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Abstract

COMBINATORIAL ANALYSIS OF TUMORIGENIC MICRORNAS DRIVING
PROSTATE CANCER
By William T. Budd; PhD
A dissertation submitted in partial fulfillment for the degree of Doctor of Philosophy at
Virginia Commonwealth University.
Virginia Commonwealth University, 2012
Major Director: Zendra Zehner; PhD Biochemistry and Molecular Biology

Prostate cancer is the leading non-cutaneous malignancy affecting men in the
United States. One in every six men will be affected by prostate cancer. Due to the high
incidence of prostate cancer, there is a need to develop biomarkers capable of identifying
tumors from benign prostatic lesions. miRNAs are small molecules that regulate protein
translation and impact cellular integrity when dysregulated. It is widely thought that
miRNAs have the potential to serve as biomarkers.
This study utilizes a unique combinatorial analysis of miRNA dysregulation to
identify key miRNAs involved in prostate tumor initiation, progression and metastasis.
Numerous dysregulated miRNAs potentially influence cancer development. A unique
bioinformatically driven, network based approach was used to rank potential miRNAs
that drive tumor progression. This study showed that miRNAs preferentially regulate
highly connected proteins and transcription factors that affect numerous downstream
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targets. Thus dysregulation of a single highly connected miRNA could severely impact
homeostatic maintenance of the tissue.
In combination with miRNA profiling of a cancer cell progression model, the
utilization of laser captured microdissection was used to separate cancer specific
microRNA portraits from background differences arising from stroma cells, lymphocytes,
and remaining normal epithelial cells. Integration of miRNA profiles with information
gathered using networks biology and targeted proteomics resulted in the identification of
a key miRNA that affects prostate cancer development and may be useful as a novel
biomarker for identification/ staging of prostate cancer.
Human miR-125b was identified as a potential miRNA suppressor of tumor
formation. Previous work has identified miR-125-b as the post-transcriptional regulator
of the ErbB2/ ErbB3 growth factor receptor family. Loss of miR-125b drives up
expression of ErbB2/ ErbB3 activating downstream PI3K/AKT and RAS oncogene
pathways. The level of miR-125b decreases 3-5-fold between benign and tumor
epithelium. Further, miR-125b decreases during the development of prostatic
intraepithelial neoplasia, which is regarded as an early indicator of prostate cancer. Thus
miR-125b may be an ideal marker of early changes indicative of cancer. Restoration of
miR-125b into highly tumorigenic, metastatic cells reduces mobility and invasion of
underlying tissues. Taken together these data show miR-125b is a tumor suppressor in the
healthy prostate.

xiv

Chapter 1
Introduction and Background
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Background
Cancer is a highly heterogeneous, multifactorial disease that results from
numerous genetic mutations, aberrant gene expression and miRNA dysregulation 1.
Prostate cancer (CaP) is the most frequently diagnosed visceral carcinoma and the second
leading cause of cancer related deaths of men in the United States 2. An estimated
241,000 men will be diagnosed in 2012 3. It is predicted that nearly 27,000 will
eventually succumb to the disease and likely that one of every six men will develop CaP
during their lifetime. The death rate increases significantly as the tumor becomes more
poorly differentiated and treatment options decline as the tumor leaves the confines of the
prostate 4. Metastatic dissemination is the single most significant event occurring during
prostate cancer progression. Despite the significance of metastasis, molecular events
surrounding tumor progression and metastasis are poorly understood.
A variety of genetic and epigenetic factors such as age, race, heredity, diet, sexual
frequency and physical activity are known to influence the development of prostate
tumors 5. Important ethnic differences exist in prostate cancer epidemiology. Diagnostic
rates vary dramatically across racial subgroups with the Hispanic male having the lowest
rate of CaP diagnosis (Figure 1-1) 3. It is known that the diagnostic rate of prostate cancer
in Hispanic men under estimates the actual number of Hispanic males with the disease as
they are less likely than their Caucasian counterparts to participate in active screening by
prostate specific antigen (PSA) analysis or digital rectal exam 6. Even though it appears
the overall diagnostic incidence of prostate cancer is slightly lower in African-Americans,
the age specific death rate is nearly two times higher. It is hypothesized that the death rate
is higher in African-Americans because they are more likely to be diagnosed at a higher
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clinical stage of tumorigenesis than their Caucasian counterparts 7. The single greatest
predictor of death from prostate cancer is the stage at diagnosis; the higher the stage at
the time of diagnosis the greater the likelihood of death. It is imperative that the
underlying causes of ethnic differentiation be determined and the disparity eliminated.
A recent study published in Cancer Causes and Control showed that lifestyle
habits did not significantly differ between African-American and white men 8. The only
potential variable that impacted prostate cancer diagnosis was education. The higher the
education level of the patient, the more likely they were to participate in active screening
methods and be diagnosed at an earlier stage. Men with graduate degrees have a lower
death rate from prostate cancer than a man with a high school diploma or less (Figure 12). Although the discrepancy is highest in African-American men, the trend applies to
men of every race. The most likely reasons for the educational variation are an increased
awareness of one’s health and better access to health care.

Diagnosing prostate cancer
Evidence clearly demonstrates that early detection of prostate tumors reduces the
likelihood of death from the disease 9. Although prostate cancer can only be definitively
diagnosed by biopsy and histological examination, screening tools such as the prostate
specific antigen (PSA) and digital rectal examination are useful in identifying patients
that need biopsy. Prostate biopsy is not without risk. Bleeding and infection are
commonly observed complications. The prostate biopsy is normally performed using a
transrectal approach guided by ultrasound imaging. There is a large risk of infection as
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Figure 1-1: Incidence and death varies among men of different ethnicities
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Figure 1-1: Incidence and death varies among men of different ethnicities
Analysis of data collected by the National Cancer Institute as part of the Surveilance,
Epidemiology and End Results program 10. Data were separated into groups by race and a
table generated using Microsoft Excel.
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Figure 1-2: Death rate from prostate cancer decreases with higher education
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Figure 1-2: Death rate from prostate cancer co-varies with race and education
Analysis of data collected by the National Cancer Institute as part of the Surveillance,
Epidemiology and End Results program 10. Data was separated into groups by race and
table generated using Microsoft Excel.

-5-

the needle passes from the rectum into the prostate. Many physicians minimize the
incidence of infection through prophylactic antibiotic administration. The goal of active
screening is to identify the population of patients that will receive the most benefit from
biopsy.
Prior to the advent of the serum PSA test, it was estimated that only 25% of all
prostate tumors were diagnosed and most were diagnosed at a later stage 9. A physician
cannot diagnose prostate cancer using a PSA analysis in isolation. PSA testing is only
useful as a potential indicator of disease 11. Studies show that in isolation the PSA is not a
reliable indicator of disease and must be considered along with a digital rectal
examination. The test is not as specific, many men have elevated PSA levels (>= 4.0
ng/ml) without any indication of cancer. It is estimated that 75% of elevated PSA assays
are not caused by cancer. There are many causes of PSA elevation including benign
prostatic hypertrophy (BPH) and infection.

Development of specific biomarkers to identify and stage prostate cancer
As PSA is not a specific indicator of prostate cancer, there exists a need to
develop reliable biomarkers that can alert health care providers to the presence of early
stage disease and distinguish indolent from aggressive tumors. Clearly, a great need
exists for the development of more accurate biomarkers. In order to develop a more
reliable marker for prostate cancer, one must understand the biological mechanism of
tumor formation, progression and metastasis.
In recent years, microRNAs (miRNAs) have emerged as an important class of
non-coding RNAs that influence post-transcriptional protein levels 12. In the presence of
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external cues and environmental stressors, miRNAs have the ability to induce rapid
changes in the proteome allowing the cell to respond in a more precise and energy
efficient manner 1. Numerous cellular processes are affected by miRNA, including
differentiation, growth/ hypertrophy, cell cycle control and apoptosis 13. Mature miRNAs
are ~ 22 nucleotides in length and regulate protein levels by binding mostly to the 3’untranslated region (3’-UTR) of a messenger RNA, inducing translational repression or
message cleavage. Aberrant expression of miRNAs contributes to the development of
many pathological conditions including cancers of the breast, prostate, thyroid, and B-cell
lymphomas 14. Even though miRNAs have been casually observed to be associated with
cancer of the prostate, there is not a clear consensus on specific miRNAs that contribute
to oncogenesis. Dysregulated miRNAs may be useful as potential biomarkers for prostate
cancer, as it has been shown that miRNAs can be exported from the cell and are found in
most biological fluids.

Biogenesis of microRNA
The generation of miRNAs is a step wise process that results in the creation of a
22 nucleotide segment of RNA that is capable of inducing mRNA cleavage or
translational repression. miRNA genes can be found as a component of a polycistronic
transcript consisting of two to seven miRNAs under the control of a common promoter,
exist in intergenic regions of the genome, or be found in an intron under the control of
that gene’s promoter 15, 16. Creation of the pri-miRNA begins in the nucleus under the
control of RNA polymerase II and ends with a several hundred nucleotide RNA molecule
that possesses a characteristic stem loop structure. The pri-miRNA has a 5’ cap and a
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poly A tail on the 3’ end (Figure 1-3) 17. While in the nucleus, a ribonuclease like enzyme
(Drosha) processes the pri-miRNA into a 70-100 nt fragment that retains the
characteristic stem loop structure called a pre-miRNA. The pre-miRNA is exported into
the cytoplasm by means of the nuclear export factor (Exportin V). Once in the cytoplasm,
the loop of the pre-miRNA is cleaved and the stems are separated by Dicer into two 2025 nt strands (mature miRNA). One of the strands accumulates and is incorporated into
the RNA induced silencing complex (RISC).

miRNA function
Most eukaryotic genes are under the influence of at least one miRNA 18. Many
genes are controlled by multiple miRNAs. Dysregulation of a single miRNA can affect a
multitude of proteins and potentially lead to a cancerous phenotype. MiRNAs regulate
target messages via several mechanisms. Perfect binding between a miRNA and the
target sequence will typically result in direct cleavage of the phosphodiester bond
between nucleotides 10 and 11 of the target mRNA 19. Message cleavage is carried out
only by RISC complexes that contain Ago2 20. Incomplete complementarity of the
miRNA to the 3’-UTR of the message is traditionally thought to result in translational
inhibition 18. Most mRNA degradation occurs through deadenylation, decapping and 5’3’ exonuclease degradation. Proteins needed for mRNA degradation have been shown to
concentrate in cytoplasmic processing bodies (PBs). Experiments have shown that
miRNAs and mRNA gene reporters also accumulate in these PBs, suggesting that colocalization of the miRNA/ mRNA may be another method of translational repression/
degradation.
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Figure 1-3: Biogenesis of microRNA

Figure 1-3: Biogenesis of miRNA
1. RNA polymerase II transcribes a 200- 700 nucleotide segment that is
polyadenylated and 5’ capped (pri-miRNA)
2. Ribonuclease enzyme (Drosha) processes the pri-miRNA into a 70-100 nt
fragment known as the pre-miRNA
3. The pre-miRNA possesses a characteristic stem loop structure
4. Exportin V exports the pre-miRNA into the cytoplasm
5. The Dicer complex recognizes the characteristic stem loop structure and cleaves
the pre-miRNA into a smaller RNA of approximately 22 nt (mature miRNA)
6. Each pre-cursor has the potential to generate two mature miRNA molecules
7. The mature miRNA recognizes complementary bases of the messenger RNA. The
greatest numbers of proven interactions have been identified in the 3’ UTR of
message. However, interactions have been observed in the 5’ UTR and within the
coding sequence.
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Many miRNA genes are dysregulated in cancer and influence tumor formation/
progression because they are located in regions of the genome that are commonly
overexpressed or deleted 21. Dysregulated miRNAs have been shown to contribute to
oncogenesis by the loss of tumor suppressing miRNAs or increased expression of
oncomiRs 22. While tumor suppressing miRNAs are lost or reduced during oncogenesis,
oncomiRs are amplified or overexpressed. Either loss of tumor suppressors or increased
expression of oncomiRs ultimately results in increased cell growth, proliferation,
invasiveness or metastasis. Aberrant expression of even a single miRNA has the
potential to influence a large number of cellular processes as it is predicted that each
miRNA has the potential to affect hundreds of proteins. Thus, dysregulation can
destabilize homeostatic balance by affecting levels of a multitude of target proteins.

Genetically related prostate cancer progression model
Through the utilization of a unique genetically related prostate cancer cell
progression model, we are able to identify miRNAs that likely contribute to prostate
cancer initiation, progression and metastasis. Cell lines were derived through the
immortalization of non-neoplastic prostate epithelium with SV40 large T antigen under
the control of a SV40 promoter 23. The parental (P69) cell line is poorly tumorigenic, and
non-metastatic. P69 cells have a lower modal chromosome number than most other
prostate cancer cell lines in use as these have been typically isolated from metastatic sites
(LnCap, DU145, and PC3). An in vivo selection process was used to create cells with
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Figure 1-4: Development of genetically related prostate cancer cell lines

Model for the development of a unique, genetically- related cancer progression model is
presented. Human prostate epithelial cells immortalized with SV40 large T antigen were
injected into a mouse and expanded using an in vivo selection process. At each passage,
the cells acquired increased tumorigenic propensity as shown. The M12 subline possesses
highly tumorigenic behavior and metastatic potential with 100% of mice injected
suffering from disseminated cancerous lesions.
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Figure 1-4: Development of genetically related prostate cancer cell lines
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increased tumorigenicity and metastatic potential. After several rounds of in vivo
selection following intra-prostatic and intra-peritoneal injections, a highly tumorigenic
and metastatic variant (M12) was isolated. M12 cells routinely metastasize in nude,
athymic mice following intra-prostatic/ intra-peritoneal injection and contain a
chromosome 16:19 translocation. Restoration of chromosome 19 in M12 cells resulted in
a variant that was less tumorigenic and non-metastatic (F6) 24. These prostate cancer cell
lines are unique as they are not derived from a primary tumor and are genetically related.
They provide a model to study the molecular events that occur during prostate
tumorigenesis and metastasis.

Identification of dysregulated miRNAs in prostate cancer cell progression model
Microarray technology has allowed researchers to simultaneously profile
hundreds to thousands of molecules in a single assay 25. The advent of array based
profiling of miRNA expression is difficult because of the nature of the molecule 26.
miRNAs are on average only 22 nucleotides in length, vary dramatically in their
abundance and melting temperature, and often only differ from one another by a single
base. Despite the challenges, several technologies have been used with a modest degree
of success 25. Radiolabeled northern blots, bead based profiling methods, oligonucleotide
arrays, and quantitative real time PCR applications have been utilized. Until recently, all
of the methods described have been limited to samples for which one can obtain a
relatively large amount of starting material.
The advent of locked nucleic acid technology has increased the sensitivity and
specificity of miRNA based arrays 26, 27. Locked nucleic acids have a reduced
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conformational flexibility through the incorporation of a methylene bridge between the
4’- carbon atom and 2’- oxygen of the ribose ring 28. Interspersion of locked nucleic acid
nucleotides among non-locked nucleotides allows for fine tuning of the melting
temperature of oligonucleotides. The inclusion of a single LNA base increases the
melting temperature 2-10°C. LNA modified probes can be optimized in such a manner
that a uniform melting temperature and normalized hybridization conditions can be
established. LNA modified probes are ideal for profiling the entire miRnome as they have
higher sensitivity and higher specificity than standard oligonucleotide probes. This
technology allows researchers to profile precious tissue with a lower amount of starting
RNA.
Several studies have reported numerous differences in miRNA expression that
arise during cancer progression 25, 29, 30. It remains to be determined for most of the
miRNAs shown to be dysregulated, whether their aberrant expression is a cause or a
consequence of cancer 31. Evidence shows that aberrant expression of a single miRNA
can induce oncogenic transformation 32. Transgenic mice that overexpress miR-155
suffer a condition that mimics lymphoblastic leukemia. Although miR-155 has been
shown to be causative in acute lymphoblastic leukemia, evidence for a potential role in
prostate cancer is unclear.
Human-miR-21 has been described as the ubiquitous solid tumor oncomiR and is
overexpressed in prostate, lung, pancreas, breast, stomach, and colon cancers 33. Despite
claims that increased miR-21 expression is observed in prostate cancer, it has been shown
that knockdown of miR-21 does not affect proliferative or invasive properties in DU145
and PC3 cancer cell lines 34. In matched human samples, there are approximately as many
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men with prostate cancer that have increased miR-21 expression as those that do not. A
role for miR-21 in the progression of CaP is not clear.
Attempts to identify a miRNA signature of prostate cancer using screens have
failed to reveal a consistent pattern that can identify malignant epithelium from its normal
counter part. The results are inconclusive and often contradictory. There are several
potential reasons for disagreement among profiles. Improper study design,
underestimated treatment of patients, underlying heterogeneity of the tissue, and platform
inconsistencies are just a few of the reasons for potential disagreement among studies 35.

Identification of key signaling proteins affecting tumorigenesis
The advent of high throughput technologies has enabled researchers to identify
hundreds of genetic mutations that lead to oncogene activation 36. Previous researchers
have shown that point mutations do not occur randomly in known oncogenes. Instead,
there exist a relatively small number of codons that are affected disproportionately. There
are many methods that can be utilized to discover somatic mutations that may be driving
cancer progression. These mutations are often described as oncogenic “hits”. Oncogenic
mutations confer a survival advantage to the cell by aberrant influence of intracellular
protein signaling pathways 37.
Common pathways that influence cancer progression are survival, growth,
apoptosis, and cell cycle control pathways. Genetic sequencing and gene expression
profiling cannot determine pathway activation. It has been shown that mRNA levels
correlate poorly with the amount of an active protein. In order to determine the activation
level of signaling proteins, proteomic technology is needed. Reverse phase protein
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microarrays (RPMA) allow for the simultaneous evaluation of hundreds of proteins at a
single time point 37.
RPMA was developed to interrogate a small number of cells and measure
multiple analytes 37, 38. RPMA arrays immobilize a protein analyte onto an array substrate
and probe with an antibody. Potentially, hundreds of samples can be adhered to a single
array. As only minute amounts are spotted onto the array, a sample can be extended
across hundreds of slides. This approach allows researchers to profile hundreds of
proteins across hundreds of samples and better characterize the intracellular signaling
proteome.

Confirmation of microRNA dysregulation in human samples
Many studies have used human tissue obtained from prostatectomy or biopsy in
an attempt to identify potential miRNA markers of cancer progression. For the most part,
these studies have failed to identify miRNAs that can be used as biological markers for
the diagnosis of prostate cancer let alone can be utilized to stage prostate tumors 39.
Nearly all of the published work using miRNA screens of human prostate tumors utilizes
homogenized tissue following gross dissection. It is likely that the tissue being analyzed
remains contaminated with other cell types such as stroma, blood vessel, nerves, smooth
muscle or lymphocytes. In order to accurately profile a tissue’s disease state, diseased
cells must be removed from surrounding tissue and examined in a pure cell population 40.
Laser capture microdissection (LCM) is a technique that allows one to isolate
pure cell populations from heterogeneous tissues 40. LCM uses infrared and/or ultraviolet
lasers to attach visualized cells to a thermolabile polymer cap. Not only can pure
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populations of normal epithelium and stroma be separated from diseased tumor
epithelium or activated stroma, but ultimately tumor cells at varying stages of disease can
be individually captured. After dissection, the captured cells can be used to analyze all
types of biological macromolecules, such as miRNAs, mRNA, or proteins can be isolated
from these pure populations of captured cells.

Systems biological perspective
It is essential to have an understanding of the individual molecules that contribute
to complex phenotypes such as cancer and metastasis 41. However, complex systems are
not just an assembly of genes, proteins, and other macromolecules. Emergent properties
arise out of complex non-linear interactions amongst all the molecules in a cell.
Traditional molecular biological and biochemical studies have uncovered many
molecules that contribute tumorigenic properties upon dysregulation. Traditional
reductionist approaches have viewed the human body as a collection of constituent parts
42

. The tradition of medicine has been to isolate and treat the defective component in

isolation and hope the result is indicative of the whole. Unfortunately, complex
phenotypes cannot be reduced to a single molecule as they discount the emergent
properties that arise from the non-linear interaction of multiple components. The
reductionist approach has been quite successful at treating many conditions but has failed
to eradicate more complicated pathologies such as cancer. Cancer is the end result of
numerous alterations in biochemical pathways and networks 43.
An alternative to the traditional reductionist philosophy is the concept of systems
biology. Systems biologists seek to gather information about multiple types of molecules
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(genes, proteins, RNA) in the cell and integrate the information in order to understand the
perturbations underlying a given pathology from a systems level. High throughput
technologies such as DNA microarray, genome sequencing, proteomics, and qRT-PCR
profiling allow for the simultaneous acquisition of thousands data points. Integration of
multiple data sources increases the likelihood of identifying key pathways involved in
cancer initiation, progression and metastasis.
Complex interactions can be modeled as a biological network with the
macromolecule represented as a node and interactions modeled as edges 1. Network
properties are described mathematically. An important indicator of molecular importance
is node degree. A highly connected node is more likely to be essential and cause disease
when dysregulated 44, 45.

Network properties identify key proteins affected by miRNA dysregulation
Traditionally, researchers using array based methods rank significance based on
relative expression differences. This method assumes that the most differentially
expressed miRNA is the most significant contributor to the observed phenotype. It is
reasonable to hypothesize that small changes in some miRNAs may effect large changes
in the tissue as some targets are more important than others. It is well known that highly
connected proteins are more likely to be essential, and disease associated 44, 45.
Perturbations of these highly connected proteins are more likely to result in diseases such
as cancer 1.
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Hypothesis
This project utilizes a unique combinatorial approach to understand the impact of
miRNA dysregulation upon prostate cancer progression. A novel isogenic prostate cancer
cell progression model has been selected as it more closely mimics tumor progression as
it occurs in vivo. I propose that miRNA profiling of these unique cell lines will better
serve to identify miRNAs that contribute to cancer progression and metastasis. Arrays
that utilize LNA™ modified probes are more advantageous than other array technologies
currently in use as they are more sensitive and more specific. Differences in miRNA
expression will be verified using quantitative real time PCR (qRT-PCR) with either
TaqMan® probes or Exiqon® LNA™ probes.
miRNA significance will be ranked not just by expression differences but rather
the identification of critical downstream protein nodes through the use of methods used in
biological network analysis. As miRNAs affect protein levels, key signaling molecules
will be measured using the RPMA format in conjunction with the George Mason
University Center for Applied Proteomics and Molecular Medicine. Integration of
miRNA profiles and proteomic data have the potential to increase the success of
identifying novel miRNAs affecting tumorigenesis in the cancer progression model. It is
our hypothesis that a combinatorial analysis of an RPMA profile and a miRNA array will
reveal dysregulated miRNAs that affect significant downstream targets imparting an
onocgenic advantage. The combination of the data revealed in the cancer cell line
miRNA screens, RPMA proteomics along with information from our networks analysis
will be used to rank the dysregulated miRNAs and each will be verified in human
samples. We propose that the utilization of laser capture microdissection to obtain a pure
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cell population from a heterogeneous prostate tumor sample will reveal miRNAs that can
be used for diagnostic purposes. Overall, this combinatorial approach will reveal
miRNAs that drive prostate cancer progression when dysregulated and may be useful as
newer, more relevant biomarkers to identify and stage prostate cancer.

Specific aims of project
•

Identify key microRNAs involved in prostate tumorigenesis using a systems
biological approach.

•

Using an Exiqon® miRNA screening platform with RNA collected from
genetically related prostate cancer cell lines. Develop a list of prioritized miRNAs
that affect key proteins involved in tumorigenesis of the prostate gland. .

•

Measure the relative expression levels of the priority miRNAs determined in aim1
using microdissected tissue of malignant cells and benign cells obtained from
flash frozen human prostate biopsy samples.

•

Modify the expression of the differentially regulated miRNAs in a prostate cancer
cell model and evaluate effects on tumorigenesis using a variety of in vitro
analyses.

•

Ultimately the effect of miRNA modulation on tumorigenic and metastatic
properties will be evaluated in male, nude, athymic mice (Future Studies).
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Chapter 2
Networks analysis reveals preferential miRNA regulation of highly connected
protein nodes
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Complex physiological processes can rarely be ascribed to a single molecule 46.
Instead, they arise out of the interaction and coordination of large numbers of proteins,
nucleic acids, and other macromolecules. Healthy organisms intricately regulate
thousands of components with remarkable fidelity and accuracy 1. Protein-protein
interactions are essential to many biological processes and mediate many of the reactions
necessary to sustain life. A key strategy to understand the molecular workings of the cell
is the systematic identification of crucial protein interactions 47.
These interactions can be modeled as a biological network with proteins
represented as nodes and interactions among the proteins represented as edges.
Topological features of the network can be described mathematically and used to infer
molecular contribution to network/cellular stability. As observed, widespread miRNA
dysregulation contributes to the development of many forms of cancer including cancer
of the prostate. This work utilized a systems based, network approach to understand the
impact of miRNA dysregulation on the overall stability of a protein-protein interaction
network (Figure 2-1).

Identification of dysregulated miRNAs contributing to prostate cancer
MiRNAs associated with prostate cancer (111) were compiled from the
miR2disease online resource 48. Utilizing the built in search function for miRNAs
associated with a specific disease, the database was queried using the term “prostate
carcinoma” to identify miRNAs related to prostate tumorigenesis and included both
causal and unspecified relationships. Using a PERL script, each miRNA was further
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evaluated to extract information regarding its expression pattern and literature references
for each dysregulated miRNA.

Proven targets of miRNAs associated with prostate cancer
A comprehensive record of proven miRNA/gene interactions was assembled from
the Tarbase and miRecords repositories of experimentally supported miRNA targets
downloaded in May 2011 49, 50. Utilizing a PERL script, multiple entries were eliminated
and both resources were combined into a single non-redundant list. Dysregulated
miRNAs contributing to prostate cancer were associated with validated targets using our
comprehensive record.
Prostate gland transcriptome profiles were obtained from the Unigene database in
order to build a protein-protein interaction network of prostate specific miRNA/ target
interactions 51. Transcripts that show any level of expression in the prostate gland were
extracted and identifiers converted to HUGO gene symbols using a PERL script. By
combining the information obtained from the miR2disease database, comprehensive
miRNA/ target interactions and the list of expressed transcripts in the prostate, we
compiled a total of 608 confirmed protein targets that are affected by miRNA
dysregulation in the prostate.

Literature mined prostate protein-protein interaction network
The Agilent literature search (v2.76) tool was used in conjunction with Cytoscape
2.8 to infer two protein-protein interaction networks 52, 53. The first was built using known
prostate cancer miRNA targets. Each protein in the candidate list of 608 known prostate
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cancer miRNA target proteins was used as a search term in the Agilent literature search
tool and the search was controlled to limited interactions to Homo sapiens with a
maximum of 10 hits per search string/ search engine. The second network was built in the
same manner using 608 randomly chosen proteins that are expressed in the prostate gland
according to the Unigene database but chosen without regard to known miRNA status 51.
Following network inference, visualization was accomplished using Cytoscape and
topological network descriptors were estimated using CentiScaPe 54.

Randomization of prostate miRNA target protein-protein interaction network
The prostate cancer miRNA target network was shuffled 50,000 times using a
degree preserving edge shuffle random network plugin developed by engineers at
Syracuse University and implemented in Cytoscape. The plugin was downloaded
(http://sites.google.com/site/randomnetworkplugin/Home) as a .jar file and installed in
the Cytoscape package. The application was run across two processors and repeated
50,000 times to generate the best results.

Transcription factor analysis
Transcription factors were compiled from the TFCAT curated catalog of
transcription factors 55. Only genes determined to be transcription factors were
downloaded and the default choice was selected for the remaining download filtering
options. The file was exported into a tab delimited text file and a PERL script utilized to
remove any redundant proteins. After filtering, there were a total of 3419 transcription
factors.
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Transcription factors targeted by miRNAs dysregulated during tumorigenesis of
the prostate were compiled by intersecting the list of miRNA targets with the table of
transcription factors using PERL. The process was repeated using the list of randomly
associated proteins.

Statistical analysis
Differences in network distributions were evaluated using an Analysis of
Variance test (ANOVA) with significance set at probability <= 0.05. All statistical
analyses were performed using JMP 8.0 (Statistical Analysis Software Cary, NC). The
distribution of node degree for the prostate miRNA targeted network and the randomly
selected prostate protein network were created using the R Project for Statistical
Computing (http://www.r-project.org/).
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Figure 2-1: Outline of process to determine network properties of miRNA targets
MiRNAs contributing to the development of prostate carcinoma were downloaded from
miR2Disease and associated with proven targets. A protein-protein interaction network
was inferred using literature references with Agilent Literature Search. Network
properties were calculated using CentiScape and pathway enrichment was estimated
using Agilent.
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Figure 2-1: Outline of process to determine network properties of miRNA targets
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Analysis of miRNA contributions to prostate tumorigenesis
Dysregulation of miRNAs may result in tumor formation and progression through
the increased expression of oncomiRs or decreased expression of tumor suppressors.
Mir2disease is a manually curated database which associates experimentally supported
miRNA dysregulation with disease 48. Consideration of only experimentally proven
miRNA/ disease associations will not reveal every miRNA that is involved in prostate
cancer. However, this approach is more favorable than approaches that consider putative
interactions as they suffer from an inherent lack of sensitivity evidenced by large
numbers of false positive predictions. A search of the miR2disease database reveal a
total of 111 miRNAs that contribute to prostate tumorigenesis and cancer progression
when significantly dysregulated. It remains to be determined whether or not miRNA
dysregulation is the cause of tumorigenesis, a consequence of tumorigenesis or both.
Previous authors had observed a global decrease of miRNA expression levels during
tumorigenesis leading to the hypothesis that most miRNAs function as tumor suppressors
56

. Our analysis using the miR2diease database finds that there are approximately as

many oncomiRs as tumor suppressing miRNAs. Sixty microRNAs showed increased
expression levels (oncomiRs) in tumor samples compared to normal tissue whereas 51
miRNAs decreased in tumor samples (tumor suppressors) (Figure 2-2).
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Figure 2-2: microRNA dysregulation in prostate cancer
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Figure 2-2: microRNA dysregulation in prostate cancer
microRNAs dysregulated during prostate cancer progression were extracted from the
miR2disease database along with their potential role in cancer development as defined by
their expression profiles 48. A Venn diagram illustrating the numbers of oncomiRs, tumor
suppressors, and miRNAs that can function as either oncomiRs or tumor suppressors was
created.
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Interestingly, there are 11 examples in which the same miRNA displays
contrasting behaviors in prostate tumors. These have the potential to act as either
oncomiRs or tumor suppressors during tumorigenesis. Their expression level may vary
depending upon the degree of cellular de-differentiation. For example hsa-miR-125b
(miR-125b) has been reported by several groups to significantly decrease during
tumorigenesis. MiR-125b coordinately regulates two members of the human epidermal
growth factor receptor family (ErbB2/HER2/ NEU, ErbBB3/HER3) 14, 25, 57, 58. Decreased
expression or loss of miR-125b results in an increase in both ERBB2/ERBB3 protein
levels thereby enhancing the invasive potential of the cell leading to tumor formation and
progression 59.
Conversely, the androgen independent LNCaP sublines (CDS1 and CDS2)
produce higher levels of miR-125b compared to the androgen dependent LnCaP sublines
58

. Treatment of androgen dependent LNCaP cells with synthetic miR-125b allowed them

to survive in androgen depleted media. The cellular effects of miR-125b under androgen
dependent conditions are mediated through the translational suppression of BAK1 14.
BAK1, a member of the BCL2 protein family, functions as a pro-apoptotic factor 60.
Suppression of pro-apoptotic factors increases the oncogenic potential of the cell.
A similar finding is observed with hsa-miR-146a, which can function as an
oncomiR in many tumors, but in androgen independent tumors functions as a tumor
suppressor 25, 61. Altogether these two examples illustrate how a single miRNA (miR125b, miR-146a) can function as a tumor suppressor or an oncomiR dependent upon
another variable, in these cases androgen dependence. Most likely similar situations
could be found for the other overlapping group members.
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Protein-protein interaction of prostate cancer miRNA targets show scale free
behavior
Nearly every biological process depends upon protein-protein interactions 62.
Disruptions or perturbations in these interactions underlie many human diseases
including cancer. Protein- protein interactions are modeled using a system based, network
approach and described mathematically. Two protein- protein interaction networks were
built with information gathered from the PubMed , Online Mendelian Inheritance in Men,
and the US Patent Office databases using the Agilent Literature Search plugin in
Cytoscape. Topological network characteristics were measured using CentiScaPe 52, 54, 63.
The first network was built using proven targets of dysregulated miRNAs shown
to contribute to the development of prostate cancer. A second similar network of
randomly sampled proteins expressed in the prostate, but chosen without regard to
miRNA status was compiled. Both the network of dysregulated miRNA protein targets
and randomly selected prostate proteins possessed a scale free form (Figure 2-3).
However, they differed in the average connectivity as measured by node degree with the
miRNA targeted network having a much higher average connectivity measure. Node
degree is a measure of interactions among the molecules in a network. In a scale free
network, as the node degree increases, the frequency observed decreases, with most
nodes having only a few connected neighbors. This functional organization commonly
seen in a complex system ensures redundancy in the system resulting in some amount of
fault tolerance 46.
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Figure 2-3: Targets of miRNAs are more highly connected than randomly chosen
proteins
Two shortest path protein-protein interaction networks were built using the Agilent
literature search function within Cytoscape 2.8 and topological measures evaluated using
CenstiScaPe 2.76. The first network was built using proven targets of miRNAs that are
dysregulated during the development of prostate cancer (Red). The other network was
built from randomly chosen proteins that are expressed in the prostate but chosen without
regard to miRNA status (Blue). Frequency distributions of the node degree for the two
shortest path networks are displayed
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Figure 2-3: Targets of miRNAs are more highly connected than randomly chosen
proteins
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MiRNAs dysregulated in prostate cancer preferentially regulate highly connected
proteins
Node degree is one topological measure that can be used to infer the contribution
of a protein towards cellular/network stability. Analysis of the average node degree
revealed an overall enrichment of highly connected proteins in the prostate cancer
miRNA target network not seen in the network of randomly selected prostate proteins
(p<= 0.0001) (Table 2-1). The average protein in the miRNA targeted network was
connected to nearly 30 other proteins. Conversely, the average protein in the randomly
chosen network was only connected to approximately 5 others. Of the top candidates in
the prostate cancer miRNA targeted network, mitogen-activated protein kinase 14
(MAPK14) was the most connected with a node degree of 290. It is important to note that
the node degree represents a maximum protein potential, not all 290 proteins will interact
with MAPK14 at the same time. Instead, MAPK14 will interact with a small number of
proteins at any one moment and the neighbors change depending upon the needs of the
cell. The most highly connected protein in our randomly generated prostate network was
only connected to 28 other proteins, a ten-fold difference. A list of prostate cancer
miRNA targeted proteins with a node degree over 200 is included in Table 2-2. This list
is rich in well known cancer related proteins, many of which are current or proposed drug
targets.
Perturbation of these highly connected nodes is more likely to negatively impact
network stability 1. It has been shown that molecules with a higher node degree are
essential to the cell and their loss often results in a disease state such as cancer 44, 45.
There is a positive correlation between protein essentiality and connectivity indicating

- 34 -

Table 2-1: Comparison of network node distribution of the prostate cancer miRNA
target network and the randomly chosen prostate protein network

Network
Prostate cancer miRNA
target protein
Random prostate protein

Mean
Degree

Standard
Deviation

Minimum Maximum

29.80

47.75

1

290

4.46

4.24

1

28
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Table 2-2: Protein nodes with connectivity degrees greater than 200
Node
degree
290

Protein
MAPK14

Name
Mitogen activated
protein kinase 14

SP1

SP1 Transcription
Factor

269

VEGFA

Vascular endothelial
growth factor

267

CASP3

Caspase 3

258

MYC

Transcription factor

254

EGFR

Epidermal growth
factor receptor

248

Cell cycle progression,
apoptosis, and cell
transformation
Cell proliferation

BCL2

B-cell lymphoma 2

247

Apoptosis

CTNNB1

Catenin Beta 1

232

Cell growth regulator and cell
adhesion

JUN

Jun proto oncogene

229

Transcription factor,
angiogenesis, apoptosis

hsa-miR-15a, hsa-miR-16, hsa-miR-30

TNF

Tumor necrosis factor

217

hsa-miR-146a

FGF2

Fibroblast growth
factor 2

216

Cell proliferation,
differentiation, apoptosis, lipid
metabolism, and coagulation
Cell proliferation,
angiogenesis

TP53

Tumor protein 53

213

Cell cycle regulation and
apoptosis

hsa-miR-129-5p, hsa-miR-125a-5p, hsa-miR1285, hsa-miR-125b

PPARG

Peroxisome
proliferator activated
receptor gamma
Estrogen receptor 1

213

Regulator of adipocyte
differentiation

hsa-miR-27b

212

Cell growth, differentiation,
and sexual reproduction

hsa-miR-302c, hsa-miR-20b, hsa-miR-19b,
hsa-miR-18a, hsa-miR-181a, hsa-miR-206,
hsa-miR-22, hsa-miR-181b, hsa-miR-193b,
hsa-miR-19a

Cell proliferation,
differentiation, adhesion, and
migration
Cell cycle control

hsa-miR-141, has-miR-128a

ESR1

TGFB1

Transforming growth
factor beta 1

208

CCND1

Cyclin D1

203

Function
Cell proliferation,
differentiation, and
transcription regulation
Cell growth, differentiation,
and apoptosis

Known miRNA
hsa-miR-124, hsa-miR-24

Angiogenesis,
vasculogenesis, and vascular
endothelial cell growth
Execution phase of apoptosis

hsa-miR-205, has-miR-200b, hsa-miR-126,
hsa-miR-93
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hsa-miR-218, hsa-miR-124, hsa-miR-29b

hsa-let-7a, hsa-let-7e
hsa-miR-24, hsa-miR-145, hsa-miR-34c-5p,
hsa-miR-34a, hsa-miR-34b*, hsa-let-7c
hsa-miR-1, hsa-miR-7,
hsa-miR-16
hsa-miR-15, hsa-miR-1, hsa-miR-20a, hsamiR-34a, hsa-miR-181a, hsa-miR-296-5p, hsamiR-15a, hsa-miR-153, hsa-miR-17, hsa-miR15b
hsa-miR-155

hsa-miR-16

hsa-miR-16, hsa-let-7b, hsa-miR-17, hsa-miR195, hsa-miR-34a, hsa-miR-20a, hsa-miR-15a,
hsa-miR-19a, hsa-miR-155, hsa-miR-503

that the more connected a protein is, the greater the likelihood that it is essential to life.
Conversely, molecules with a lower number of connecting neighbors are not as likely to
disrupt the system when they are perturbed. Disease causing genes are more likely to
encode highly connected proteins 64, 65. This analysis indicated that miRNAs have a
strong likelihood of impacting the network structure and dysregulation is more likely to
affect essential proteins causing diseases like cancer.
Randomization of the prostate cancer miRNA targeted network was performed to
estimate the likelihood that this arrangement arose out of chance. The network was
compared to a null model made by a shuffled (50,000 X) version of itself 66. Shuffling
was accomplished using an algorithm that preserves the overall node degree distribution
in order to emulate the properties found in the prostate miRNA targeted network. The
randomized networks did not result in a mean clustering coefficient (C = 0.029) similar to
the protein-protein interaction network (C = 0.621). This measure is evidence that the
arrangement of the proteins in this network is not random, but results from clusters of
associated proteins, as would be expected in a complex, living system. Randomly
generated networks of the same degree and distribution do not maintain this modularity.

OncomiRs regulate more highly connected proteins than tumor suppressors
A one way analysis of variance (ANOVA) revealed statistically significant
connectivity differences among the targets of oncomiRs and targets of tumor suppressing
miRNAs (F2, 503 = 6.2821, p=0.002). Oncogenic miRNAs showed a regulatory preference
towards more highly connected proteins. While the connectivity of an oncomiR target
was 39, the average connectivity of a tumor suppressor miRNA target was only 27 other
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proteins (Table 2-3). Interestingly, the targets of the 11 miRNAs that can function as
tumor suppressors or oncomiRs depending upon a second variable exhibited a much
higher average target node degree (61) than either oncomiRs or tumor suppressors alone.
Cancer related proteins in general show greater node degree and higher
connectivity than non-cancer associated proteins 67, 68. The protein products of tumor
suppressing genes are known to be more centrally located and more highly connected
than the products of oncogenes 69. In our analysis we found that the connectivity of
oncomiR targets was higher than the targets of tumor suppressing miRNAs. It is
important to remember that miRNAs are negative regulators of protein translation and the
targets of oncomiRs would be tumor suppressive proteins. This analysis confirmed that
miRNA dysregulation contributed to the development of prostate cancer.

Highly connected proteins possess more than one miRNA binding site
A comparison of proteins in the prostate cancer miRNA targeted network
revealed that there was a positive correlation between protein connectivity and the
number of different experimentally proven miRNA binding sites in the 3’-UTR (Figure
2-4). That is, as a protein interacts with a higher number of other proteins, it is more
likely to be regulated by multiple miRNAs. MiRNAs may act cooperatively through the
simultaneous interaction of multiple miRNA species with the 3'-UTR of a transcript 70.
In the case of vascular endothelial growth factor (VEGFA), multiple distinct binding sites
were observed in the 3’-UTR. Transfection with varying combinations of miRNAs
resulted in additive levels of translational repression. VEGFA was the third most highly
connected protein in our prostate cancer miRNA target network (Table 2-2).
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Table 2-3: MicroRNA target connectivity changes with the role of the miRNA
Description

OncomiR
(Expression increases during
tumorigenesis)
Tumor Suppressor
(Expression decreases during
tumorigenesis)
Both
(Exhibits both behaviors dependent
upon a second variable)

Number of Nodes
Regulated by miRNA
Type
192
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Node Degree
39

276

27

37

61

Figure 2-4: Proteins regulated by multiple miRNAs are more likely to be highly
connected
Proteins were grouped according to the number of miRNAs that have been proven to
regulate their translation. The number of miRNAs that regulate a protein (independent
variable) was plotted against the average node degree of the targets (dependent variable)
and a best fit linear equation was generated (y = 17.91 x - 7.9; r2= 0.831). Proteins that
were regulated by 6-10 miRNA species were grouped into a single group because there
were only a few proven examples regulated by more than 6 miRNAs.
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Figure 2-4: Proteins regulated by multiple miRNAs are more likely to be highly
connected
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Although not included in table 2-2, another example of a highly connected protein
under multiple miRNA regulation is the cyclin dependent kinase inhibitor 1A (CDKN1A).
CDKN1A was regulated by the largest number of unique miRNAs (28) and connects to
190 other proteins 71. Many tumor suppressor pathways are under the control of
CDKN1A and its decreased expression increases the likelihood of cancer development 72.
As a potent cell proliferation inhibitor, CDKN1A is an important modulator of the cyclin
dependent kinases (CDK) that regulate cell cycle progression through the G1/S
checkpoint. Loss of the CDK inhibitor allows the cell to proceed through the cell cycle
and diminishes the cell’s response to DNA damage. Increased expression of any of the
miRNAs that regulate CDKN1A would decrease protein levels and induce oncogenic
transformation. This analysis showed that important proteins were regulated by multiple
miRNAs and dysregulation of any of these miRNAs could result in a disease state such as
cancer.

MiRNAs preferentially regulate highly connected transcription factors
Trans acting factors such as transcription factors and miRNAs control
levels of proteins in the cell. However, each differs in their mode of regulation.
Transcription factors typically bind up stream of a gene and either potentiate or inhibit
transcription. miRNAs have been shown to preferentially bind the 3’ UTR of the mRNA
transcript affecting protein translation through several mechanisms. Transcription factors
that are targeted by miRNAs dysregulated during prostate cancer progression are more
highly connected than randomly chosen transcription factors (p-value <0.001) (Figure 25). This analysis identifies another mechanism of miRNA regulation. By targeting highly
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connected transcription factors, miRNAs can exert a great influence over a large number
of proteins. For example, SP1 is one of the most highly connected proteins in our
network with a connectivity of 269.

Summary
Cancer is a multifactorial disease that arises from the accumulation of genetic and
epigenetic changes that lead to oncogenic transformation causing cells to proliferate
uncontrollably. MiRNAs are an important class of translational regulatory agents that
affect cell proliferation, differentiation, cell cycle control, and apoptosis. Increased
expression of oncomiRs or decreased expression of tumor suppressors leads to
uncontrolled cell proliferation, invasion and metastasis.
Because of the scale free design of complex systems and a higher average node
degree, miRNA protein targets are more vulnerable to targeted attacks that may lead to
catastrophic cellular failures 46. A single dysregulated miRNA has the potential to induce
a significant number of cellular changes by affecting multiple highly connected proteins.
It is important to consider that modulation of a single highly connected protein node has
the potential to affect hundreds of downstream targets thereby modifying multiple
pathways resulting in considerable physiological fluctuation. During the development of
prostate cancer, there is wide scale dysregulation of miRNA expression affecting
numerous highly connected, essential disease causing proteins and numerous cellular
pathways (Figure 2-6).
By combining knowledge of miRNA dysregulation with topological descriptors
of a protein-protein interaction network, we may identify important proteins contributing
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to tumor progression that have not been previously described. This analysis will be used
to identify newer, more relevant indicators of prostate cancer and may offer insights
toward the development of targeted molecular therapies. These methods will be used to
biologically evaluate the role of miRNA dysregulation in cell lines and human samples.

- 44 -

Figure 2-5: Connectivity of transcription factors
Transcription factors were compiled from the TFCAT curated catalog of transcription
factors 55. Transcription factors targeted by miRNAs dysregulated during tumorigenesis
of the prostate were compiled by intersecting the list of miRNA targets with the table of
transcription factors using PERL. The process was repeated using the list of randomly
associated proteins. Data are presented as a whisker plot that was generated using R and a
table of associated values.
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Figure 2-5:

Network Type
miRNA targeted

Number Mean
Standard Min
(467)
connectivity Deviation
112
46.01
60.45
1

Max
269

(24%)
Randomly chosen

122

4.34

4.15

(26%)
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1

24

Figure 2-6: Model of miRNA regulation

Figure 2-6: Model of miRNA regulation
Using the data obtained from the systems level network analysis a model of miRNA
regulation of prostate cancer was created.
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Chapter 3

Identification of dysregulated microRNAs contributing to prostate tumorigenesis

- 48 -

Tightly controlled gene regulation is essential to every biological process. Failure
to control gene regulation can result in cellular disease or death. Cells have devised many
methods for regulating protein levels. The central dogma of biology of one gene, one
mRNA, one protein as envisioned by Francis Crick is in need of modification. Complex
feedback loops involving RNA splicing, gene regulation at the transcriptional and
translational level have been discovered. In order to understand a complex disease
phenotype, researchers must consider a greater role for RNA than traditionally envisioned.
In the past decade, microRNAs have emerged as an important class of posttranscriptional regulators of protein levels. Nearly every biological process is under the
control of at least one miRNA and it is thought that most protein levels are influenced by
miRNA expression. Important highly interconnected proteins are often under the control
of more than one miRNA 73.
Dysregulation of microRNA expression contributes to a number of pathological
conditions and diseases including cancer of the prostate 22. Conversion of neoplastic
growth from benign to metastatic dissemination is a step wise process that likely involves
numerous biological macromolecules, often including RNA, protein, and DNA.
Accumulating evidence suggests that multiple miRNAs are dysregulated during tumor
formation, progression and metastasis 25. Both miRNA losses and gains of miRNA
function have been shown to contribute to the development of neoplasm.
As previously discussed, miRNAs can function as either suppressors of tumor
formation or promoters of tumorigenesis (oncomiRs). The increased expression of
oncomiRs or loss of tumor suppressors can induce neoplastic transformation. It has been
shown that over one hundred miRNAs are dysregulated during the development of
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prostate cancer 73. Comparison of high throughput analyses of miRNA expression in the
poorly tumorigenic, non-metastatic P69 cell line and its highly tumorigenic, metastatic
variant M12 variant can reveal miRNAs that may contribute to tumorigenicity. As we
have shown, miRNAs preferentially regulate highly connected protein targets.
In this study, we propose that our unique combinatorial approach will reveal
dysregulated miRNAs contributing to carcinogenesis. Utilizing a prostate cancer cell
progression model, we will determine potential miRNAs that may contribute to a
cancerous phenotype. Dysregulated miRNAs will be ranked using a unique networks
based approach and expression differences will be confirmed by single miRNA analysis.
Expression of proposed dysregulated miRNAs will be evaluated using RNA extracted
from pure cell populations obtained by LCM in order to validate differential expression
from benign to tumorigenic epithelium. The contribution of these miRNAs to controlling
P69 and/or M12 cell behavior will be further investigated by a variety of in vitro
experiments.

Materials and Methods
Cell culture
Cells are cultured at 37° C in RPMI1640 with L-glutamine obtained from Gibco
supplemented with 5% fetal bovine serum, 5μg/ml insulin, 5μg/ml transferrin, and 5
μg/ml of selenium (ITS from Collaborative Research Bedford, MA). Inhibition of
bacterial contamination was accomplished with the addition of Gentamycin (0.05mg/ml).
M12 cells stably transformed with the p-SIREN (M12+miR-17-3p and M12+miR-125b)
vector were maintained with Puromycin (100 ng/ml). F6 cells were maintained with
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Geneticin (200 μg/ml) 24. All tissue culture cells were grown in T75 flasks and split when
confluent. Cells were pelleted after trypsin (0.25% in EDTA) digestion by centrifugation
at 5000 RPM for five minutes. Trypsin inactivated by washing the cells in serum
containing media. After washing, cell pellets were flash frozen in liquid nitrogen after
washing and stored for at least 24 hours.

Cell pellet RNA extraction
Total RNA was extracted from cell pellets described above using the miRVana™
miRNA isolation kit from Ambion per manufacturer’s instructions. Briefly, after cell
lysis total RNA was bound to a glass fiber filter and eluted with a proprietary elution
buffer. After isolation, RNA concentration was estimated using a Biorad® Smart Spec™
3000 spectrophotometer, diluted to a concentration of 100ng/ml and stored at -80°C for at
least 24 hours.

MicroRNA profiling
Real time PCR profiling was performed using the miRCURY LNA ™ Universal
RT microRNA PCR system (Exiqon, Denmark). Human Panel I was used to identify
dysregulated miRNAs in the P69 cell line versus its metastatic derivative M12. Duplicate
samples were compared using 25ng and 50 ng of RNA as input. Briefly, RNA input was
converted to cDNA using supplied reagents and enzymes (4μl of 5x reaction buffer, 9μl
of nuclease free water, 2μl enzyme mix, 1μl synthetic RNA spike in, and 5 μl of RNA
diluted to 5 ng/ul). The reaction was incubated for 60 minutes at 42° C and the enzyme
was heat inactivated for 5 minutes at 95°C. Real time PCR plates were run on an
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ABI7900 HT (95°C for 10 mins, 40 cycles at 95°C-10sec, 60°C-1 min, ramp rate
1.6°C/s). Threshold and baseline were set manually according to recommendations in the
supplied protocol. After correcting for interplate variability, cycle threshold (CT) values
were normalized to the global mean of all miRNA expression. Initial data analysis was
performed using Exiqon GenEx software and all values are reported as fold changes
relative to P69. miRNAs exhibiting greater than 2-fold expression differences in both sets
of arrays were considered to be significant and selected for further analysis.

Ranking of dysregulated miRNAs
Significantly dysregulated miRNAs were ranked according to the sum network
connectivity of proven targets. Proven targets of miRNAs were obtained by combining
miRecords and Tarbase into a single non-redundant list. A protein-protein interaction
network was inferred by using each targeted protein as a search term in the Agilent
literature search (v2.76) tool implemented in Cytoscape 2.8 52, 53. Network properties
were developed using CentiScape. 54.

TaqMan® based miRNA assay
Verification of mature miRNA expression was confirmed using single assays by
TaqMan® miRNA assay (Life Technologies, Grand Island, NY). Briefly, cDNA was
synthesized in a 25μl reaction volume from 20 ng of total RNA using the TaqMan®
MicroRNA Reverse Transcription kit. Reactions were incubated at 16°C for 30 minutes,
42°C for 30 minutes and inactivated at 85°C for 5 minutes. Each cDNA was analyzed in
triplicate by quantitative PCR using sequence specific primers in an ABI7300 qRT PCR
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system (Applied Biosystems). Each individual assay was performed in a 20μl reaction
volume with 1.33μl of cDNA, 1.0μl specific miRNA assay, 10μl TaqMan™ Universal
PCR Master Mix II with no AMP Unerase and 7.67μl of nuclease free water. Reactions
were incubated in a 96 well plate at 50°C for 2 minutes, followed by 95°C at 95°C and 40
cycles of 95°C for 15 sec/ 60°C for 60 sec.

SYBR green based qRT-PCR
Quantification of mature miRNA expression was carried out using the miRCURY
LNA™ Universal RT miRNA PCR (Exiqon, Denmark). Synthesis of cDNA was
accomplished by incubating 50ng of total RNA in a 20μl reaction volume of 5X reaction
buffer (4μl), nuclease free water (9μl), enzyme mix (2μl), synthetic RNA control spike in
(1μl) and template RNA (4μl). cDNA reaction was incubated for 60 minutes at 42°C and
enzyme inactivated for 5 minutes at 95°C. Following synthesis, the cDNA is diluted 20
fold with nuclease free water. Real time PCR amplification was performed in a 10μl
reaction with 4μl of diluted cDNA template, 5μl SYBR® Green Master Mix (Exiqon,
Denmark), and 1 μl of PCR primer mix. The reaction was run in an ABI 7300 (Applied
Biosystems) at 95°C for 10 min, followed by 40 cycles of 95°C (10 sec), 60°C (60 sec) at
a ramp rate of 1.6°C/sec. Melt curve analyses were run on each reaction to verify single
product amplification. Threshold and baseline were set manually according to
recommendations in the supplied protocol.
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qRT-PCR data analysis
Relative quantities of miRNA levels were determined using the 2-ddCT method of
Livak et al after normalization with RNU48 as a standard reference 74. All samples were
performed in triplicate and the average cycle threshold (CT) value was determined. The
average CT was normalized by subtracting the average CT of RNU48 (dCT). All samples
were compared to the parental P69 cell line by subtracting the experimental dCT from the
dCT value of the parental cell line (calibrator).

Laser capture microdissection
Human prostate samples were obtained from frozen core samples of radical
prostatectomy samples available from VCU’s Tissue and Data Acquisition and Analysis
Core. All samples were obtained with approval from the VCU institutional review board.
All slides were reviewed by a board certified pathologist with expertise in prostate cancer
diagnosis. Briefly, 8 μm tissue slices were placed on uncharged glass slides, dehydrated
with progressively increasing concentrations of ethanol, stained with hematoxylin and
eosin (H&E). Laser capture microdissection was performed using an Arcturus Veritas
machine. Areas of interest were captured onto CapSure® Macro LCM caps (Life
Technologies, Grand Island, NY). At least ten slides were captured for each patient
included in the study.

RNA extraction of LCM samples
Total RNA was extracted from LCM extracts using the PicoPure® RNA Isolation
Kit (Life Technologies, Grand Island, NY). The manufacturer’s protocol was followed.
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Following dissection of tissue, the LCM caps were incubated for 30 minutes at 42°C in
50μl of extraction buffer. Cell extracts were stored at -20°C until ready for RNA
extraction. Similar cellular lysates from successive slides were pooled into a single tube
and mixed with 1 volume of ethanol (70%). The lysate/ethanol solution was loaded onto
a high recovery MiraCol™ column and centrifuged at 100xg for 2 minutes followed by
16,000xg for 30 seconds. RNA was recovered in an 11μl volume. Concentration and
quality were measured using an Agilent RNA 6000 Pico kit with the Agilent Bioanalyzer
2100.
Cloning of miR-125b into M12 cells
M12 cells (500,000) were stably transformed with the human miR-125b sequence (as
underlined) 5’GATCCGTCCCTGAGACCCTAACTTGTGATGTTTACCGTTTAAATCACAAGTTA
GGGTCTCAGGGA TTCTTTTTTTCTAGAG-3’ and its complement 5’AATTCTCTAGAAAAAAAGAATCCCTGAGACCCTAACTTGTGATTTAAACGGT
AAACATCACAAGTTAGGGTCTCAGGGACG-3’ into the BamHI and EcoRI cloning
sites of the pSIREN vector (BD Biosciecnes, SanJose, CA). Cells were transformed with
purified plasmid (2.0 μg) using TransIT-LT1 (4.0 μl) transfection reagent (Mirus
BioCorp, Madison, WI). Resistant cells were selected with 400 ng/ml Puramycin.

Migration assay
Cells were detached from the plate using 2.0 ml of CellStripper™ (CellGro®,
Manassas, VA) and pelleted at 5000 rpm for 5 minutes. Cells were washed in serum free
RPMI 1640 and re-suspended in serum free media at a concentration of 2.5x105cells/ml.
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200 μl of cell suspension (50,000 cells) was added to the top chamber of a 6.0μm pore
size ThinCert™ tissue culture insert (Greiner, Monroe, NC). 0.5 ml of serum containing
media was added to the lower chamber supplemented with 10 ng/ml of EGF (Figure 3-1
A). Cells were incubated at 37°C for 20 hours. Media was removed from both chambers
and cells were fixed in 0.025% glutaraldehyde in PBS for 20 minutes after removal of all
media from both chambers. Following fixation, inserts were stained with 0.1% crystal
violet in PBS for 30 minutes and washed with sterile deionized water. Non-migratory
cells were removed from the top surface with a sterile cotton applicator and inserts
mounted on a glass microscope slide. Cells were counted in 10 random fields at a 200 X
magnification. Data are presented as the mean sum of migratory cells in 10 random fields
± standard error.

Invasion assay
Invasion assays are carried out in a manner similar to the migration assays. At
least 30 minutes prior to extracting cells, 60 μl (diluted 1:10) of Culturex® reduced
growth factor basement membrane is added to the top chamber of the ThinCert™ tissue
culture insert and incubated at 37°C for gelling (Figure 3-1 B). After ensuring that the
basement membrane has gelled, the remainder of the protocol is identical to the migration
assay. Data are presented as the mean sum of invasive cells in 10 random fields ±
standard error.
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Figure 3-1: Migration and invasion assay

Figure 3-1: Migration and invasion assay
A. Illustration of the experimental setup for an individual well migration assay.
B. Illustration of the experimental setup for an individual well invasion assay.
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Results

Identification of miRNAs dysregulated during tumorigenesis
Understanding the molecular perturbations that underlie cancer initiation,
progression and metastasis are critical to identify newer, more relevant biomarkers. Many
model cell lines have been used to explore prostate cancer progression. Most are derived
from metastatic sites and thus may not represent the best model for elucidation of early
indicators of cancer formation 75-77 . Rather than being isolated from a metastatic site,
these cells were obtained from normal prostate tissue immortalized with SV40 large T
antigen (P69) and cycled through male athymic nude mice to obtain the tumorigenic
variant (M12) discussed earlier 23. This unique isogenic model may provide insights to
the molecular causes that initiate cancer formation.
Quantification of miRNA levels is difficult. The length of the mature miRNA is
22-23 nucleotides, the same length as traditional PCR primers. Increasing the difficulty is
the fact that often miRNAs only differ from one another by a single base. Thus, it is very
difficult to design a primer that can discriminate single base differences in such small
molecules. The advent of locked nucleic acid (LNA™) modified primers increases the
specificity and sensitivity of qRT-PCR for miRNAs.
Utilizing a LNA™ based array panel that profiles the most relevant, currently
identified miRNAs (386 miRNAs), we discovered 180 miRNAs that significantly change
at least two-fold from the parental P69 cell line to the highly tumorigenic M12 cell line
(Table 3-1). Eighty six miRNAs were lost as the tissue becomes more
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Table 3-1: miRNAs dysregulated during tumorigenesis

microRNA
hsa-miR-125b
hsa-miR-500
hsa-miR-127-3p
hsa-miR-382
hsa-miR-411
hsa-miR-299-5p
hsa-miR-576-5p
hsa-miR-620
hsa-miR-409-3p
hsa-miR-144
hsa-miR-410
hsa-miR-548c-3p
hsa-miR-136
hsa-miR-323-3p
hsa-miR-379
hsa-miR-583
hsa-miR-377
hsa-miR-539
hsa-miR-487b
hsa-miR-376c
hsa-miR-325
hsa-miR-135b
hsa-miR-337-5p
hsa-miR-598
hsa-miR-99a*
hsa-miR-432
hsa-miR-20b
hsa-miR-597
hsa-miR-135a
hsa-miR-183
hsa-miR-15b
hsa-miR-509-3p
hsa-miR-376a
hsa-miR-19a
hsa-miR-495
hsa-miR-223
hsa-miR-198
hsa-miR-302b
hsa-miR-185*
hsa-miR-346
hsa-miR-425*
hsa-miR-886-3p
hsa-miR-891a
hsa-miR-212
hsa-miR-514
hsa-miR-383

Fold Difference
4.76E-06
0.001
0.002
0.003
0.004
0.004
0.004
0.008
0.008
0.012
0.013
0.014
0.015
0.015
0.018
0.026
0.031
0.034
0.035
0.036
0.042
0.045
0.054
0.056
0.061
0.062
0.064
0.068
0.068
0.072
0.079
0.080
0.086
0.091
0.098
0.111
0.114
0.114
0.115
0.116
0.119
0.134
0.138
0.148
0.149
0.150
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Behavior
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor

microRNA
hsa-miR-493
hsa-miR-342-3p
hsa-miR-187*
hsa-miR-631
hsa-miR-369-5p
hsa-miR-449a
hsa-miR-185
hsa-miR-100
UniSp6 CP
hsa-miR-214
hsa-miR-127-5p
hsa-miR-572
hsa-miR-21
hsa-miR-146a
hsa-miR-134
hsa-miR-302c*
hsa-miR-625*
hsa-miR-27a
hsa-miR-296-5p
hsa-miR-335
hsa-miR-376b
hsa-miR-31
hsa-miR-525-5p
hsa-miR-191
hsa-miR-196b
hsa-miR-654-5p
hsa-miR-187
hsa-miR-339-5p
hsa-miR-720
hsa-miR-140-3p
hsa-miR-146b-5p
hsa-miR-181b
hsa-miR-506
hsa-miR-30b
hsa-miR-629
hsa-miR-203
hsa-miR-449b
hsa-miR-27b
hsa-let-7a
hsa-miR-138
hsa-miR-298
hsa-miR-665
hsa-miR-126*
hsa-miR-152
hsa-miR-423-5p
hsa-miR-502-5p
hsa-miR-151-5p
hsa-miR-324-5p
hsa-miR-576-3p

Fold Difference
0.153
0.160
0.168
0.174
0.182
0.191
0.209
0.209
0.224
0.242
0.252
0.259
0.260
0.264
0.271
0.280
0.287
0.300
0.309
0.316
0.321
0.323
0.341
0.349
0.350
0.365
0.370
0.371
0.374
0.392
0.394
0.409
0.409
0.416
0.426
0.452
0.459
0.463
0.480
0.490
2.0
2.1
2.1
2.1
2.2
2.2
2.2
2.2
2.3
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Behavior
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
Tumor Suppressor
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR

microRNA
hsa-miR-330-3p
hsa-miR-302a
hsa-miR-7
hsa-let-7c
hsa-miR-615-3p
hsa-miR-933
hsa-miR-148a
hsa-let-7d
hsa-miR-22
hsa-miR-33a
hsa-miR-450a
hsa-miR-210
hsa-miR-29c
hsa-miR-491-5p
hsa-miR-365
hsa-miR-30d
hsa-miR-545
hsa-miR-602
hsa-miR-589
hsa-miR-148b
hsa-miR-374a
hsa-miR-668
hsa-miR-431
hsa-miR-200a
hsa-miR-130b
hsa-miR-32
hsa-miR-10a
hsa-miR-204
hsa-miR-22*
hsa-miR-486-5p
hsa-miR-326
hsa-miR-30c-2*
hsa-miR-96
hsa-miR-371-5p
hsa-miR-181c
hsa-miR-518e
hsa-miR-10b
hsa-miR-188-5p
hsa-miR-642
hsa-miR-99a
hsa-miR-130a
hsa-miR-888
hsa-miR-890
hsa-miR-608
hsa-miR-370
hsa-miR-338-3p
hsa-miR-1
hsa-miR-518a-3p
hsa-miR-497

Fold Difference
2.3
2.4
2.4
2.5
2.6
2.6
2.6
2.6
2.7
2.7
2.7
2.7
2.7
2.8
2.8
2.8
2.8
2.9
2.9
2.9
2.9
3.0
3.1
3.1
3.2
3.3
3.3
3.4
4.1
4.2
4.4
4.5
4.7
4.7
4.7
5.0
5.2
5.3
5.8
6.1
6.4
6.5
7.2
7.8
8.0
8.3
8.5
8.6
8.7
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Behavior
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR

microRNA
hsa-miR-595
hsa-miR-124
hsa-miR-9
hsa-miR-301b
hsa-miR-381
hsa-miR-570
hsa-miR-518b
hsa-miR-139-5p
hsa-miR-196a
hsa-miR-662
hsa-miR-105
hsa-miR-516a-5p
hsa-miR-873
hsa-miR-596
hsa-miR-517a
hsa-miR-199a-3p
hsa-miR-217
hsa-miR-518c*
hsa-miR-211
hsa-miR-299-3p
hsa-miR-33b
hsa-miR-491-3p
hsa-miR-498
hsa-miR-147
hsa-miR-373*
hsa-miR-517c
hsa-miR-451
hsa-miR-133b
hsa-miR-524-3p
hsa-miR-133a
hsa-miR-551b
hsa-miR-375
hsa-miR-153
hsa-miR-622
hsa-miR-147b
hsa-miR-34a

Fold Difference
9.5
9.5
9.6
10.7
10.9
11.3
11.6
11.7
12.8
13.2
13.4
13.6
14.6
14.9
15.9
16.5
20.1
20.3
26.0
27.5
29.9
37.8
51.4
54.2
59.2
68.4
68.5
68.9
85.7
92.9
152.2
191.0
240.0
365.0
522.1
1850.8
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Behavior
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR
OncomiR

tumorigenic, that is they function as potential suppressors of tumor formation. The
average expression difference of all tumor suppressors is 100-fold i.e. they are 100-fold
higher in the P69 cell line compared to the M12 variant. Expression of the remaining 94
dysregulated miRNAs increases as the tumorigenicity increases (oncomiRs). OncomiRs
have an average of 45-fold difference when compared to the P69 cells. The overall
number of tumor suppressors and oncomiRs is similar to that found using our global
networks approach where we found approximately as many tumor suppressors as
oncomiRs. Interestingly, the average connectivity of an oncomiR target is higher than the
average target of tumor suppressor miRNAs (Table 2-3). It is reasonable to hypothesize
that greater miRNA fold changes are needed to induce phenotypic alterations if the
targets are not as highly connected.
Human miR-125b is the most dysregulated tumor suppressor and is essentially
lost in the M12 cells. Conversely, hsa-miR-34a is much greater in the M12 cells
compared to the P69 cells. As discussed in chapter 2, the miR2disease database lists 111
miRNAs that have been experimentally shown to contribute to the development of
prostate cancer 48. In our model system, 76 of the 111 miRNAs in miR2disease are
dysregulated. This suggests that our cell progression model is a relevant indicator of
prostate cancer progression and may be useful to assess which miRNAs are causative to
prostate cancer and serve as useful biomarkers.
Microarray technology has increased the ability of researchers to simultaneously
profile thousands of molecules at a single time point. Because of their power, microarrays
have become popular tools among molecular biologists. Important considerations when
evaluating array based studies are the validity of the results, and universality of findings
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78

. Repeat experiments are critical to eliminate noise in data. In this study, we profiled

two cell lines in duplicate. All miRNAs reported in Table 3-1 were found to be
significantly dysregulated in both sets of arrays. The primary goal of microarray analyses
is to accurately identify differential molecular regulation affecting biological processes. It
is essential that identified miRNAs be validated using traditional techniques such as qRTPCR. Studies have shown that 71% of mRNAs identified to be dysregulated using
microarray were confirmed using qRT-PCR assays 79. However, the fold difference does
not always replicate. This finding suggests that array based methods are valid as
screening tools but true expression differences are only accurate using a single assay
format.

Network properties for ranking microRNA dysregulation
The cost to confirm every potentially dysregulated miRNA identified in a
microarray experiment is prohibitively expensive. Few labs have the financial or physical
resources needed to carry out such validation. Therefore, most labs choose a subset of
genes, proteins, or miRNAs to validate. Many factors affect the choice of a gene set
including relative difference, biological function, availability of reagents, and investigator
preference. A traditional approach has been to prioritize molecules with the greatest
expression difference as such expression differences are more likely to validate 78.
This approach may overestimate the importance of differential expression. It is
reasonable to suspect that smaller changes in some miRNAs may exert a greater
influence in tissue behavior, if they modulate the expression of more important proteins.
Indeed, our analysis has shown a preference for miRNAs to regulate highly connected
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protein nodes (Figure 2-6). Thus a single dysregulated miRNA can affect hundreds of
downstream targets by affecting the level of one highly connected protein. In this study
we chose a subset of genes for further studies using network properties for proven targets
of each miRNA. A total of eight miRNAs were chosen for validation based on their sum
network connectivity (Table 3-2).
Dysregulated miRNAs with a range of connectivity indices were chosen (201330). Interestingly, two of the miRNAs with the highest connectivity index, were also
the two most differentially expressed miRNAs (hsa-miR-125b and hsa-miR-34a). Three
miRNAs chosen had a sum connectivity of over 1000 each. When multiple highly
connected miRNAs are dysregulated there is a great potential to affect many signaling
pathways simultaneously. Hsa-miR-1 has the highest connectivity of all miRNAs in our
analysis, potentially influencing 1330 downstream targets. Again, it is important to reiterate that this index reflects a global potential. It is unlikely that all 1330 proteins are
affected at the same time due to both differential protein and miR expression in various
cell types. Instead, proteins will interact with one another in a variety of conditions.
Expression profiles comparing levels in M12 and P69 cells of each chosen
miRNA were determined using the ddCT method by Livak et al. Based on array results, 5
of the miRNAs chosen seem to function as oncomiRs (Figure 3-2). Their expression is
higher in the highly tumorigenic, metastatic M12 cell line. As mentioned previously,
miR-34a is the most dysregulated oncomiR. Its expression is approximately 1800 times
higher in the M12 cell line than it is in the P69 cell line. The sum connectivity of proven
protein targets of miR-34a is 1208. As the expression change is quite dramatic, and the
connectivity of its targeted proteins is very high, it is reasonable to suspect that
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Table 3- 2: Subset of miRNAs chosen for further validation

microRNA

Targets

Degree

hsa-miR-375

Mxi1 Ahr C1QBP YAP JAK2 ADIPOR2 YWHAZ
Insm1 USP1 XBP-1 MTPN

20

hsa-miR-127-3p *

BLIMP-1, BCL6

52

hsa-miR-200a

ERBB2IP, ZEB1, ZEB2, ELMO2, SIP1 and 7
others

56

hsa-miR-146a *

CDKN3, BRCA1, MCM10, IRF-5, ROCK1and
others

504

hsa-miR-22

PTEN ESR1 BMP7 PPARA MAX

565

hsa-miR-125b *

DICER, ERBB2, ERBB3, CDKN2A, BAK1, UBE21,
LIN28, ID3, and others

1194

hsa-miR-34a

CYCLIN D1 BCL2 CCND1 WNT1 E2F3 NOTCH2
MYCN Delta1 CDK6 SIRT1 VEGF c-MET MEK1
AXIN2 MYB JAG1 MYC NOTCH-1

1208

hsa-miR-1

TPM3, PIM-1, HDAC4, c-MET, TPM1, PARG1 and
others

1330

*- potential tumor suppressors
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Figure 3-2: Differential expression of oncomiRs determined using Exiqon’s
miRCURY human panel I
A profile of the miRnome was obtained using the miRCURY ready to use PCR human
panel I, V2 (Exiqon, Denmark). The experiment was run in duplicate using 20 and 50 ng
RNA as starting material. Manufacturer’s protocol was followed and data are presented
as the mean expression fold difference of M12 compared to P69. Positive numbers
represent an increased expression in M12 cells. Error bars represent the standard
deviation of fold changes between the two duplicate assays. Note the broken y axis to
depict the discrepancy between miR-22 to miR-34a better.
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Figure 3-2: Differential expression of oncomiRs determined using Exiqon’s
miRCURY human panel I

Fold Change (M12/ P69)
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dysregulation of miR-34a may induce an oncogenic event. Even though miR-1 is only 8fold higher in M12, it is likely to have a great effect on the tumorigenic properties of the
cell as it targets a large number of highly connected proteins.
Three of the miRNAs chosen for validation from the array seem to function as
tumor suppressors (Figure 3-3). miR-125b is several thousand fold higher in the nontumorigenic parental cell line (P69). Its expression is nearly undetectable in the M12
subline. HSA-miR-146a is the least differentially expressed tumor suppressor included in
our study. Its level is nearly four times higher in the P69 cells.
An additional miRNA was chosen to be validated not because of its connection to
the network, but because of other biological interests. miR-127-5p is an alternative
transcript that comes off of the same precursor as miR-127-3p. 80. Many miRNAs have
the ability to produce two functional miRNAs from the same pre-miRNA 81. Although
they are produced from the same precursor, miR-127-5p and miR-127-3p do not
accumulate at equal levels in the cell. There appears to be a preference towards
accumulation of miR-127-5p at the expense of miR-127-3p (Figure 3-4). Note the
difference in y-axis scale between Figures 3-3 and 3-4. In the latter figure log
transformation was not used in order to optimize the display of differential expression
between miR-127-5p and miR-127-3p.

Validation of miRNA dysregulation using locked nucleic acid primers
Since the advent of qRT-PCR, there have been numerous improvements to the
process. Several methods exist that allow quantification of the starting cDNA input.
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Figure 3-3: Differential expression of tumor suppressors determined using Exiqon's
human miRCURY screen panel I

0
hsa-miR-146a

hsa-miR-127-3p

hsa-miR-125b
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-20

-25
microRNA

Figure 3-3: Differential expression of tumor suppressors determined using Exiqon's
human miRCURY screen panel I.
A profile of the miRnome was obtained using the miRCURY ready to use PCR human
panel I, V2 (Exiqon, Denmark). The experiment was run in duplicate using 20 and 50 ng
RNA as starting material. Manufacturer’s protocol was followed and data are presented
as the log transformed mean expression fold difference of M12 compared to P69. Log
transformation was used as to reflect the differences in expression. Negative numbers
represent a decreased expression in M12 cells. Error bars represent the standard deviation
of fold changes between the two duplicate assays.
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Figure 3-4: Differential regulation of mature miRNAs produced by same premiRNA using miRCURY screen panels
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Figure 3-4: Differential regulation of mature miRNAs produced by same premiRNA using Exiqon's human miRCURY screen panels
Analysis of the levels of miR-127-5p and miR-127-3p obtained from profile of the entire
miRnome. Data was obtained using the miRCURY ready to use PCR human panel I, V2
(Exiqon, Denmark). The experiment was run in duplicate using 20 and 50 ng RNA as
starting material. Manufacturer’s protocol was followed and data are presented as the
mean expression fold difference of M12 compared to P69. Values less than 1 represent an
decreased expression in M12 cells. Error bars represent the standard deviation of fold
changes between the two duplicate assays.
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SYBR green is a DNA intercalating agent that fluoresces when bound to double-stranded
DNA 82. In a qRT-PCR reaction it serves as a reporter and its fluorescence increases
exponentially with each cycle of the reaction. The amount of input material is quantified
once the reporter activity exceeds an arbitrary threshold (Cycle Threshold, CT). CT
values decrease linearly as the amount of starting material is increased. Thus, a sample
with more starting material will display a lower CT value.
LNA™ modified probes were used in this study to validate expression differences
of the eight miRNAs chosen using our unique networks based approach plus the two
additional miRNAs (miR-127-5p, miR-34b). All miRNAs chosen for validation are
described by sequence and accession number in Table 3-3 as names often change as
miRBase is updated.
Performance of LNA™ modified primers was verified using RNU48 and miR34a
as a representative primer set (Figure 3-5). RNU48, traditionally used as a normalization
standard, exhibited a linear decrease in CT values as the amount of starting material
increased (r2=0.9985). Normalization is accomplished by subtracting the CT value of
RNU48 from the raw CT value of the experimental probe (delta CT). The delta CT of
miR-34a decreases linearly as the amount of starting material increased (r2= 0.9986). As
both LNA™ modified probes exhibited the expected linear decrease with extremely good
correlation coefficients, it is reasonable to expect that all probes available from the
manufacturer will perform in a similar manner. Exiqon advises that each of their primer
sets have been validated to specifically bind only a single miRNA and demonstrates the
same linear correlation as we observed for RNU48 and miR-34a.
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Table 3- 3: Information and sequence for each profiled miRNA
miRNA
hsa-miR-375
hsa-miR-127-3p
hsa-miR-127-5p
hsa-miR-146a
hsa-miR-22
hsa-miR-200a
hsa-miR-1
hsa-miR-125b
hsa-miR-34b
hsa-miR-34a

Sequence
UUUGUUCGUUCGGCUCGCGUGA
UCGGAUCCGUCUGAGCUUGGCU
CUGAAGCUCAGAGGGCUCUGAU
UGAGAACUGAAUUCCAUGGGUU
AAGCUGCCAGUUGAAGAACUGU
UAACACUGUCUGGUAACGAUGU
UGGAAUGUAAAGAAGUAUGUAU
UCCCUGAGACCCUAACUUGUGA
CAAUCACUAACUCCACUGCCAU
UGGCAGUGUCUUAGCUGGUUGU
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miR Base Accession Number
MIMAT0000728
MIMAT0000446
MIMAT0004604
MIMAT0000449
MIMAT0000077
MIMAT0000682
MIMAT0000416
MIMAT0000423
MIMAT0004676
MIMAT0000255

Figure 3-5: Verification of locked nucleic acid probes
RNA (20.0 ng) isolated from M12 cells was converted into cDNA using the miRCURY
LNA™ Universal RT PCR system (Exiqon, Denmark). cDNA was diluted to an
approximate concentration of 0.2 ng/μl, 0.4 ng/μl, and 0.8 ng/μl. Each reaction was
performed in triplicate with individual LNA™ modified oligonucleotide primer sets and
real time PCR amplification using SYBR Green. RNU48 was used as an endogenous
standard (A). The experimental probe (miR-34a) was normalized by subtracting the
corresponding CT value of RNU48 (B). Both plots compare CT values to the amount of
starting material.
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Figure 3-5: Verification of locked nucleic acid probes
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Cancer formation occurs in a step wise process beginning with initiation and
ending at metastasis. Along the way, many factors affect and influence the development
of cancer. MiRNAs, genes, proteins, and epigenetic mechanisms all contribute during
each step of the process. It is important to identify the specific stages of cancer
progression that each molecule affects. Utilizing our genetically related prostate cancer
progression model, we assayed levels of each dysregulated miRNA in the P69, M2182,
and the M12 cell lines. Each step in the progression model was described previously
(Figure 1-4). As discussed, array based methods are useful for identifying trends in
dysregulation, but true fold changes can only be detected using a single assay format.
Results from microarry screens versus single miRNA analyses will be compared in the
following section. Where appropriate these results will be correlated to those reported in
the literature.

miR-22
Human miR-22 increased during the development of the M12 cells approximately
4-fold (Figure 3-2). Single assay analysis confirms that miR-22 does indeed increase in
the M12 subline when compared to the P69 cells (Figure 3-6). Interestingly, the bulk
increase occurred during the early phases of tumorigenesis from P69 to M2182. There is
only a slight increase in miR-22 from the M2182 cells to the M12 cells.
In the literature, cell lines derived from primary prostate tumor and from distant
metastatic sites display increased levels of miR-22 83. DU145 cells stably transduced
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Figure 3-6: Validation of oncomiRs using single assay format
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Figure 3-6: Validation of oncomiRs using single assay format
RNA (50ng) was reverse transcribed into cDNA using a universal RT PCR system
(Exiqon, Denmark). Each assay was conducted in triplicate with an LNA modified
oligonucleotide primer set. SYBR green was used as the fluorescent reporter and the PCR
reaction was performed in an ABI7300. Data are presented as the mean fold change
between each cell type relative to P69.
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with a retroviral vector expressing pri-miR-22 formed a higher number of colonies in
soft agar as compared to a nonsense control. Increased expression of miR-22 negatively
correlates with the level of PTEN (a known tumor suppressor). In situ hybridization on a
prostate tumor microarray slide reveals a majority of prostate tumors express miR-22,
while non-tumorigenic tissue does not.
The phosphatase and tensin homog (PTEN) represses the PI3K-AKT pathway
which promotes proliferation, invasiveness, and motility 84. Mutations or deletions of
PTEN are common and occur frequently in many cancers including CaP. Dosagedependent inactivation of PTEN effects tumor progression, invasion and latency. Subtle
reductions in PTEN can increase tumorigenic propensity of cells and complete loss of
PTEN often gives rise to an aggressive, metastatic phenotype. miR-22, along with other
miRNAs, reduces the level of PTEN. Increased expression of miR-22 can lead to a
decrease of PTEN levels and accelerate the PI3K/ AKT pathway. Altogether our results
agree with these reported findings and support the importance of miR-22 to prostate
cancer progression implicating it as a potential oncogenic miRNA.

miR-200a
According to the profiling results, miRNA-200a increases in the M12 subline
compared to the P69 cells. In a single assay format using LNA™ primers, we also
observed an increase in miR-200a expression as tumorigenicity increased but to a higher
level (13-fold) than what was observed in the array (Figure 3-6).
Conversely, most studies seem to find that miR-200a functions as a tumor
suppressor with decreased expression upon tumor formation. Multiple studies have

- 78 -

shown that the miR-200 family is essential in maintenance of an epithelial phenotype 85,
86

. Loss of expression of miR-200a induces an epithelial to mesenchymal transition (EMT)

through loss of ZEB1/ ZEB2 repression. The EMT is essential for a cell to detach from
its neighbors and become motile. There are many markers that indicate a cell has
undergone an EMT including increased expression of vimentin and n-cadherin, nuclear
localization of β-catenin and loss of e-cadherin 87.
However, there may exist opposite actions for miR-200a that are tumor or tissue
type specific. For example, in endometrial endometroid carcinomas (EEC) there is
significantly increased expression of all miR-200 family members 88. Specific inhibition
of miR-200a in EEC cell lines decreases proliferation and growth. Although not
statistically significant, Lin et al observed a tendency towards an increased expression of
miR-200a in bladder cancer 89.
Interestingly, we observed a dramatic increase in the level of miR-200a in the
highly tumorigenic and metastatic M12 cell line. There is a slight increase in the relative
level of miR-200a in the intermediate M2182 cells. Expression of miR-200a
exponentially increases from M2182 to the M12 cells which exhibit a more tumorigenic
phenotype. Other work in our lab shows M12 cells to be highly invasive and motile 90.
Along with the increased metastatic potential, there is decreased expression of e-cadherin,
increased expression of vimentin and nuclear localization of β-catenin proving that M12
cells have undergone an EMT switch.
On the surface, it appears that the results found in this study are contradictory.
However, there are numerous targets of miR-200a and it is likely that additional targets
remain to be discovered. Regulation of a single target by a miRNA is only partially
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understood. It remains to be determined how a miRNA chooses its target when faced
with dozens of possibilities. Sequence complementarity, free energy of binding, and
mRNA levels may potentially influence which targets are regulated inside of a cell under
various conditions. It is becoming clear that multiple types of miRNA interactions are
common and it is unlikely that a single miRNA will always serve as either an oncomiR or
tumor suppressor in all cell types. Due to this multiplicity of interactions, it is essential to
dissect the role of miRNA dysregulation in context of specific types of cancer requiring
additional experimentation. In this model of cancer progression, it appears that miR-200a
functions as an oncomiR.

miR-1
Predominantly thought to induce cardiac/skeletal muscle differentiation and
development, miR-1 also increases during the development of prostate cancer (Figure 3-6)
91

. Similar to miR-200a, the level of miR-1 increases dramatically as the cells progress

from an intermediate stage of tumor progression towards a more oncogenic phenotype.
Results of the single miRNA assay agree with the overall trend obtained using the
mIRCURY array based platform but the fold change observed differed. As seen for miR200a, analysis of miR-1 using a single assay revealed a much higher fold difference (7fold) than observed using the array.
There are dozens of targets proven to be regulated by miR-1, the most well
described is HDAC4 a histone deacetylase. Androgen insensitivity is commonly observed
in most disseminated prostate carcinomas. Localization of HDAC4 in the nucleus of
androgen insensitive cancer cell lines was observed and hypothesized to contribute to the
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development of the hormone refractive phenotype 92. In the nucleus, HDAC4 represses
genes that induce cellular differentiation. The mechanisms for sequestration of HDAC4
in the nucleus of the androgen insensitive epithelial cells are not well understood. It is
possible that accumulation of miR-1 in the cytoplasm by some yet undefined mechanism
may play a role in the nuclear localization of HDAC4. Thus miR-1 may be an important
oncomiR that drives prostate cancer progession.

miR-375
Exhibiting a greater than 10-fold increase in the M12 subline, miR-375 has been
shown by other groups to be of potential interest in the development of prostate cancer 93.
miR-375 accumulates in the cytoplasm of tumor epithelial cells and increases in 82% of
patient tumors. In our cell progression model, miR-375 exhibits an interesting behavior.
Its expression decreases slightly in the early stages of tumorigenesis and increases as the
cells move toward a more tumorigenic, metastatic phenotype (Figure 3-6). The overall
observation of miR-375 behavior agrees in both the array and single assay experiments.
However, the fold change measured in the array based format was higher than that
determined using the single assay experiment reversing the trend seen earlier for miRs200a and -1. Interestingly, the detection of circulating miR-375 in blood has been
suggested as a biomarker for CaP, which would agree with our data suggesting that miR375 functions as an oncomiR 94.
The X-box binding protein 1 (XBP1) is a basic region-leucine zipper transcription
factor involved in the unfolded protein response system 95. Accumulation of unfolded
proteins (ER stress) in the lumen of the endoplasmic reticulum (ER) leads to activation of
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pathways that decrease protein expression, increase degradation and protein folding 96.
As ER stress continues to develop, induction of pro-apoptotic pathways occurs.
Inadequate responses to ER stress can cause a cell to proliferate uncontrollably.
Downregulation of XBP1 inversely correlates with prostate cancer progression ie as
XBP1 decreases the Gleason grade of the prostate tumor increases 95. miR-375 has been
shown to target XBP1 causing translational inhibition of the protein leading to increased
ER stress. Increased expression of miR-375 may lead to CaP progression.

miR-34a
In our cell model, miR-34a functions as an oncomiR and is approximately 5-fold
higher in M12 than in P69 cells (Figure 3-6). Although the miRNA screen and individual
assays agree in trend, again there is disagreement in fold differences. The miRNA screen
dramatically over estimated the difference of miR-34a between the P69 and M12 cells.
Similar to miR-375, earlier stages of pathogenesis display decreased levels of miR-34a.
As the cells move toward a more oncogenic state, the level of miR-34a increases.
Traditionally thought to be a tumor suppressor regulated by P53, there is evidence
that miR-34a may be highly cell type/tumor type dependent 97, 98. Nearly 90% of prostate
tumors show high levels of miR-34a using an in situ hybridization technique 98.
Knockdown of miR-34a with an antagomir in HeLa cervical cancer and MCF breast
cancer cells resulted in decreased proliferation. It is hypothesized that increased
expression of miR-34a in tumors may result in an anaerobic metabolic capacity. It is well
known that many solid tumors contain hypoxic regions due to structural and functional
abnormalities in supporting blood vessels 99. Increases in the anaerobic potential of
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tumors can sustain cell growth and proliferation in spite of the lack of oxygen due to
increases in expression of miR-34a. Our analysis suggests that miR-34a acts as an
oncomiR in our cell model.

miR-146a
Human miR-146a displays opposing behaviors as the cells become more
tumorigenic. In the early stages of oncogenesis (M2182), miR-146a expression increases
approximately 2-fold (Figure 3-7). However; as the cells move to the more highly
tumorigenic, metastatic phenotype, expression of miR-146a decreases dramatically (60fold).
Interestingly, a literature search reveals that miR-146a displays contradictory
behaviors dependent upon androgen sensitivity 100. In high grade, hormone refractory
prostate cancer, there is a loss of miR-146a expression. There exists an inverse
correlation between miR-146a expression and severity of CaP. Increased tumorigenicity
is accomplished through the Rho-ROCK1 pathway 101. ROCK1 is a member of the RhoGTPase family, driving tumorigenesis by imparting an unlimited proliferative potential,
ability to evade apoptosis, and establishment of distant metastastic lesions 102. Some
evidence suggests that ROCK1 may contribute toward the EMT and aid in extravasation
of cancer cells from their non-tumorigenic neighbors. Thus loss of miR-146a may induce
an oncogenic transformation and miR-146a may be a potential biomarker for CaP
progression.
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Figure 3-7: Validation of tumor suppressors using single assay format
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Figure 3-7: Validation of tumor suppressors using single assay format
RNA (50 ng) was reverse transcribed into cDNA using a universal RT PCR system
(Exiqon, Denmark). Each assay was conducted in triplicate with an LNA modified
oligonucleotide primer. SYBR green was used as the fluorescent reporter and PCR
reaction was performed in an ABI7300. Data are presented as the mean fold change
between each cell type relative to P69.
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miR-127-3p
In our model, the level of miR-127-3p drops dramatically during the early phases
of cancer cell progression and is not found to be expressed in the M12 cells (Figure 3-7).
Like many miRNAs, miR-127-3p resides in a polycistronic transcript in which all
components are under the control of a common promoter. As mentioned, pri-mir-127
gives rise to two fully functional mature miRNAs.
Literature shows that miR-127-3p is a component of the miR-433/miR-127 cluster
on chromosome14 that is expressed in the normal, non-tumorigenic prostate gland 103, 104.
Methylation of a specific CpG island in tumor cells silences expression of the mir-127
precursor, while not affecting other members of the cluster. Treatment of the tumor cell
with 5'-Aza-CdR results in activation of pri-mir-127 confirming a role for methylation in
regulating miR-127-3p expression. miR-127-3p expression correlates with a less
tumorigenic, non-metastatic phenotype.
B-cell lymphoma 6 (BCL-6) is a known target of miR-127-3p (Table 3-2) 104.
BCL-6 is a transcriptional repressor best known for its role in the development of
lymphoma. However, its expression increases in several solid tumors including tumors of
the prostate. A well known target of BCL-6 repression is the programmed cell death 2
(PCD2) gene, that is involved in apoptosis 105. Induction of BCL-6 protects cells from
apoptosis, allowing cells to proliferate in spite of the accumulation of genetic mutations.
Decreased expression of miR-127-3p due to promoter methylation leads to accumulation
of BCL-6 and subsequent repression of PCD2 allowing cells to escape apoptosis and
proliferate uncontrollably. Thus miR-127-3p functions as a tumor suppressor.
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miR-127-5p
As pri-mir-127 gives rise to two functional mature miRNAs, it is expected that
silencing of the precursor would result in decreases of the level of both mature miRNAs.
Our analysis confirms that both levels of miR-127-3p and miR-127-5p decrease as the
cells gain tumorigenic properties.

miR125-b
Human miR-125b was greatly decreased in the highly tumorigenic, metastatic
M12 cell line (Figure 3-7). In early stages of tumorigenicity, miR-125b levels decrease
and continue to decrease as oncogenesis proceeds. Overall from P69 to M12, there is
approximately a 20-fold drop in the level of miR-125b. Again, this number does not
agree with the fold change found using the miRCURY Human Panel where miR-125b is
barely detectable in the M12 variant giving rise to a less accurate number. In spite of this
discrepancy, both methods confirm a highly differential expression of miR-125b. There
are many proven targets of miR-125b including the epidermal growth factor receptors
ErbB2 and ErbB3 106. Increased levels of ErbB2/ ErbB3 lead to uncontrolled cellular
proliferation and inhibition of apoptosis through activation of the AKT pathway. Patients
with metastatic, hormone-refractory CaP all showed an increase in EGFR expression 107.
Overexpression of EGFR receptors has been shown to be associated with poor outcomes
from CaP 108.
A recent study that compared matched prostate tumorigenic epithelium to benign
epithelium revealed significant down regulation of miR-125b 109. Decreased expression
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of miR-125b can be used as a potential biomarker for the discrimination of malignant
from benign epithelium. Due to the evidence of involvement of the EGFR pathway in
prostate cancer progression, miR-125b makes an attractive therapeutic target as well.
Increasing expression of miR-125b in highly tumorigenic and metastatic prostate cancer
cells may decrease tumorigenicity by inhibition of the EGFR family of growth factor
receptors. In this cell progression model, miR-125b clearly functions as a tumor
suppressor.

Summary of cell line data
Numerous changes occur during the transition from a poorly tumorigenic
phenotype to a highly oncogenic state. There are many miRNAs dysregulated as a cell
gains increased tumorigenic propensity. In this study, we identified approximately 200
miRNAs with altered expression patterns that may contribute to the development of CaP
using an array based format. A subset of these miRNAs was chosen based on their
interaction with critical proteins and their expression was analyzed across a cancer
progression model. Overall the expression patterns determined using the array based
format were confirmed using the single miRNA assay, but in some cases the fold changes
did not agree across the two methods. Nevertheless, literature searches confirmed that
each miRNA may indeed contribute to cancer progression through the modulation of
important cellular pathways. The possible interplay of these pathways in regulating CaP
will be further explored below.
Interestingly, two of the chosen miRNAs regulated the PI3K/ AKT pathway. As
discussed, loss of miR-125b leads to increased levels of ERBB2/ ERBB3 accelerating
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cell proliferation and inhibition of apoptosis (Figure 3-8). Increased expression and
accumulation of miR-22 leads to decreased levels of PTEN a known inhibitor of PI3K.
Loss of PI3K repression leads to increased cell proliferation and avoidance of apoptosis.
Utilization of in vitro models of cancer progression and metastasis has occurred
since the advent of the HeLa immortalized cell line. Since that time, hundreds of cell
lines have been created that are used to study nearly every form of cancer. CaP has been
traditionally studied using three major cell lines and their derivatives (Du145, LnCaP,
PC3).
The cell lines used in this research are unique. The primary cell used in this study
is derived from non-tumorigenic tissue, not from metastatic lesions. The highly
tumorigenic, metastatic sublines were created using in vivo selection methods. As such,
they are genetically related and offer an insight into the molecular perturbations that
underlie tumorigenesis and metastasis. In vitro models of cancer progression offer many
advantages; they are easy to handle, virtually limitless, essentially homogeneous, and are
relatively inexpensive to study 110.
Potential limitations of in vitro research include; accumulation of genetic
mutations as cells propagate in culture, contamination of cell lines by bacteria, inability
to replicate in vivo structure, and elimination of environmental cues by separation of cells
from their stroma. Although, there are limitations to in vitro assays, they still provide an
opportunity to elucidate molecular alterations affecting cancer development. For these
reasons, it is highly unlikely that a single model system can accurately reflect all aspects
of disease progression and it is important to utilize a variety of methods to ensure that
findings from cell lines replicate growth of tumor in man. Molecular changes observed in
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Figure 3-8: Model of miRNA dysregulation of PI3K/ AKT pathway
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Figure 3-8: Model of miRNA Dysregulation of PI3K/ AKT Pathway
Evaluation of miRNA expression changes using the Exiqon LNA™ miRCURY system
revealed the loss of miR-125b with an increase in miR-22 as cells gain tumorigenic
potential. The literature shows that mR-125b and miR-22 regulate the PI3K/ AKT
pathway. Combined dysregulation of both miRNAs may affect oncogenesis through
pathway modulation. Protein nodes in red are known inducers of tumor formation. The
node in blue is a well described tumor suppressor, and yellow nodes are miRNAs that
inhibit their protein targets.
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cell lines must be confirmed in human tissue and its role in prostate cancer defined. It is
unclear if many of the observed expression differences are causal or simply as a result of
tumorigenic behavior.

Confirmation of miRNA dysregulation in human tumors
Transformation of benign prostate cells to disseminated metastatic lesions can
best be understood in the context of the native environment of the prostate gland.
Determining molecular changes contributing to pathogenesis in the prostate is
complicated by the heterogeneity of the tissue. Relevant cell populations often only
comprise a small percentage of whole tissue 111. Ideally, expression profiling will be
carried out in pure cell populations as to minimize the confounding variables contributed
by heterogeneous cell populations.
To confirm findings, miRNA dysregulation was assessed in tumors obtained after
radical prostatectomy. In consultation with a board certified pathologist (Ema Dragoescu,
MD), approximately 25 potential fresh, frozen samples were identified and examined for
evidence of prostate cancer. Following prostatectomy, core samples are obtained from the
removed prostate. An attempt is made to obtain a representative core sample containing
regions of prostate tumor using external palpation. Many of the core samples evaluated
did not meet inclusion criteria for this study. Either the amount of tumor was inadequate
or there were not enough benign glands for matched comparison. Of the samples
evaluated, four were found to be suitable for study inclusion as they contained both
benign and tumorigenic epithelial glands. One of the four patients identified was
eventually excluded from the study due to an inability to obtain adequate RNA to analyze
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as core samples missed most of the tumor. Ideally, additional samples will be profiled in
the future. However, one is limited to the number of prostatectomy procedures performed
in their facility, patient consent, and adequate levels of tumor in the core samples.
Pure cell populations can only be obtained from a heterogeneous tissue with
techniques such as laser capture microdissection 40, 112. LCM allows for direct
visualization of the tissue and extraction of selected cells using UV or IR laser pulses.
Selected cells are adhered to a polymer and are utilized for downstream analysis of
biological macromolecules.
Although there have been numerous array based studies utilizing human prostate
tissue, there is little agreement on specific miRNAs dysregulated during tumorigenesis 90.
A potential reason for disagreement among studies may be contamination of tumor tissue
with adjacent smooth muscle, stroma, blood vessel, lymphocytes, and benign epithelium.
Whole prostate tissue stained with H&E is visualized microscopically and cells of interest
are selected (Figure 3-9a). Often, core samples contain several tissue types. It is not
uncommon to find regions of high grade adenocarcinoma located immediately adjacent to
benign epithelial glands. Nearly pure populations of the selected cell type are captured
onto the polymer cap and residual tissue is left behind (Figure 3-9b and 3-9d). LCM
analysis is important as findings from whole tissue may be complicated by the presence
of unrelated, contaminating tissue such as prostatic urethra (Figure 3-9c). Previous
studies that evaluate miRNA expression using homogenized whole prostate tissue are
likely to be contaminated with other tissue types. Cell specific /tumor specific profiles
can be obscured when whole tissues are homogenized and extracts are used in
downstream applications. LCM is necessary to minimize confounding variables and
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Figure 3-9: Laser capture microdissection of human prostate tissue
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Figure 3-9: Laser capture microdissection of human prostate tissue
Human prostate tissue obtained after prostatectomy was flash frozen in liquid nitrogen.
Samples stained with hematoxylin and eosin (H&E) following dehydration with ethanol
and xylene were mounted on uncharged glass slides. Representative tissue samples
displaying the heterogeneity of prostate tissue are shown (A). Following microdissection,
only regions of stroma remained. Epithelial tumor cells were extracted and retained for
analysis (B). LCM is required to minimize variation due to tissue heterogeneity. Regions
of Prostatic urethra are visible in panel C and if included in a whole tissue sample could
complicate analysis (C). Epithelial tumor cells are retained on LCM cap (D).
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obtain expression profiles that are truly reflective of the tumorigenic components of the
gland. Ideally, different grades of tumor tissue would be separated from one another and
their expression profile quantified in isolation. Within the tumor component of tissue, it is
normal to find glands of varying grades and stages. This approach assesses differential
regulation of miRNA within each distinct phase of tumor progression. However; when
using fresh frozen tissue, time is a limiting factor.
In order to obtain RNA that adequately represents the expression profile of the
tissue, dissection must be completed within 30 minutes. Due to the time limitation, it is
difficult to completely isolate tumor sub-types from one another. Thus in this study,
whenever fresh frozen tissue was utilized, all tumor sub-types were grouped together.
Future studies will further characterize miRNA dysregulation in tumor sub-types using
formalin-fixed paraffin embedded (FFPE) prostate samples. Ideally, fresh frozen samples
will be compared to their FFPE counterpart to minimize inter-patient variability. In this
study, we have evaluated one FFPE patient sample to profile miR-125b behavior across
epithelial sub-types. The expression of other selected miRs was analyzed in the three
remaining frozen tissue samples (Figure 3-10 through Figure 3-12).
Evaluation of all proposed oncomiRs revealed that there is not one miRNA in our
sub-group that universally increases as cancer progresses (Figure 3-10 – Figure 3-12). It
is expected that there will be great variation in the expression profile of miRNAs 113 .
Differences in genetic sequence, epigenetic regulation and acquisition of somatic
mutations may lead to disease and differential miRNA dysregulation. Some miRNAs
demonstrate common patterns of expression that suggest their regulation may be
genetically inherited.
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Figure 3-10: Evaluation of miRNA dysregulation in patient 09-362-V002
RNA (50ng) was reverse transcribed into cDNA using a universal RT PCR system
(Exiqon, Denmark). Each assay was conducted in triplicate with an LNA™ modified
oligonucleotide primer set. SYBR green was used as the fluorescent reporter and the PCR
reaction was performed in an ABI7300. Data are presented as the mean fold change
between tumor cells relative to benign epithelium. OncomiRs predicted to be
dysregulated during tumorigenesis are displayed in Panel A. Tumor suppressors are
shown in Panel B.
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Figure 3-10: Evaluation of miRNA dysregulation in patient 09-362-V002
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miR-125b

Figure 3-11: Evaluation of miRNA dysregulation in patient 08-347-V007
RNA (50ng) was reverse transcribed into cDNA using a universal RT PCR system
(Exiqon, Denmark). Each assay was conducted in triplicate with an LNA™ modified
oligonucleotide primer set. SYBR green was used as the fluorescent reporter and the PCR
reaction was performed in an ABI7300. Data are presented as the mean fold change
between tumor cells relative to benign epithelium. OncomiRs are displayed in panel A
and tumor suppressors are shown in panel B.
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Figure 3-11: Evaluation of miRNA dysregulation in patient 08-347-V007
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miR-125b

Figure 3-12: Evaluation of miRNA dysregulation in patient 09-225-V002
RNA (50ng) was reverse transcribed into cDNA using a universal RT PCR system
(Exiqon, Denmark). Each assay was conducted in triplicate with an LNA™ modified
oligonucleotide primer set. SYBR green was used as the fluorescent reporter and the PCR
reaction was performed in an ABI7300. Data are presented as the mean fold change
between tumor cells relative to benign epithelium. OncomiRs are displayed in panel A
and tumor suppressors are shown in panel B.
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Figure 3-12: Evaluation of miRNA dysregulation in patient 09-225-V002
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miR-125b

It has been shown that some miRNAs differ in their expression patterns between
African-American and Caucasians demonstrating that different human populations vary
in their global miRNA expression patterns. Due to the high degree of variance, it is
essential that researchers profile a large number of patients to identify key miRNAs that
may contribute to CaP progression. However, at this point we only had three samples to
profile and some interesting circumstances are discussed below which could contribute to
the lack of universal findings.
Due to technical limitations in acquiring use of the LCM facility, one sample
remained stored at -80° C after mounting onto slides for an extended period of time ie 6
months (08-347-V007). Thus, RNA extracted from this patient may be of dubious quality
and not accurately reflect all miRNA changes (Figure 3-11). Due to limited RNA
availability not all miRNAs could be assessed.
Another patient (09-225-V002) presented with an interesting morphological
condition. The glands of the prostate were atrophied. Although the attending pathologist
described the condition as benign, the miRNA expression profile suggests otherwise.
There is essentially no difference in oncomiR expression between the atrophied glands
and the tumor epithelium (Figure 3-12). It is possible that prostatic atrophy is not a
benign lesion but may be an early form of cancer. Consistent with this hypothesis,
literature shows that other authors have demonstrated that atrophied glands have
increased production of proliferative markers, and decreased levels of apoptosis 114.
Prostatic atrophy seems to be a pre-cursor to prostatic intraepithelial neoplasia and
prostate carcinoma and is not the same as normal prostatic epithelium.
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One patient (09-362-V002) exhibited expected increased expression for all
proposed oncomiRs with the exception of miR-200a (Figure 3-10). As discussed, there
are opposing roles for miR-200a that are likely to be tumor type dependent and this
discrepancy is justifiable. We put the most stock in this sample, as it was freshly prepared.
Cells were captured and RNA was extracted within 4 days. Moreover, the tissue
illustrated little abnormalities in cell type composition. In addition, we obtained
significant yields of high quality RNA from this individual as attested by analysis of
sample composition on a bioanalyzer. However, these results need to be confirmed with
additional human samples.

Profiling of tumor suppressors in human tissue
Contrary to our analysis of oncomiRs, all of the tumor suppressors identified in
our cell progression model were confirmed in each patient sample analyzed (Figure 3-10
– Figure 3-12). miR-127-3p and miR-127-5p both function as tumor suppressors;
however, there remains some form of differential regulation. Although differential
expression was observed in the cell lines, human samples showed a reverse trend with
higher levels of the 3p strand. miR-127-3p showed 3-4-fold higher expression levels
when compared to miR-127-5p in human tumor samples.
miR-125b showed significantly decreased expression (~5-fold) in all human
samples analyzed thus far. Again this fold change is not as significant as estimated using
the array based platform, but remains exciting nonetheless. As discussed, miR-125b is
one of two miRNAs chosen that regulate the PI3K/AKT pathway leading to increased
cell proliferation and apoptosis inhibition. Loss of miR-125b results in increased
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expression of ERBB2/ERBB3, two members of the family of epidermal growth factor
receptors. Anther study has shown widespread, but not universal downregulation of miR125b during the development of prostate cancer 115.
This analysis indicates that it is easier to lose expression of a tumor suppressing
miRNA rather than increase expression of oncomiRs. Loss of miRNA expression can be
brought about by a number of events. Pre-cursor miRNAs are cleaved into their mature
functional molecule by Drosha and Dicer processing. Differential expression of Drosha
and Dicer could account for some of the loss of miRNAs in tumor tissue 116. Literature
shows that Dicer levels are differentially regulated in various prostate tumors. 117
Furthermore, over half of miRNA genes are located in regions of the genome that
are sensitive to loss of heterozygosity (LOH). Epigenetic modifications have been shown
to effect numerous miRNAs as well. Often hypermethylation of miRNA promoters
inhibits expression of the pri-mirna thus decreasing the overall level of mature miRNA
available.
An ideal biomarker would be able to distinguish malignant cells from benign cells
before histological changes occur as therapy is more likely to be successful. The loss of
miR-125b in the tumor cells may be a potential indicator of cancer initiation and
progression. In order to determine if miR-125b decreases in the early stages of cancer
development, analysis of FFPE archived prostate samples was used to measure miR-125b
in various types of prostate epithelium (Figure 3-13). Dissection of FFPE samples is not
time limited and provides an ideal opportunity to more finely resolve changes that occur
during tumor progression.
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Interactions between cells and their microenvironment contribute to the
maintenance of tissue homeostasis 118. Intricate intercellular signaling networks between
the stroma and epithelium help to maintain normal tissue integrity. Communication
failure within either the stromal cells or the epithelial cells may induce oncogenic
transformation and contribute to cancer initiation or progression. Generation of a reactive
stroma is generally thought to occur during early phases of tumor progression 119.
Identification of miRNA changes driving the switch from normal to reactive stroma may
result in a unique early indicator of prostate cancer. A slight increase in the level of miR125b is observed in the stroma of this sample compared to benign epithelial tissue (Figure
3-13).
Benign prostatic hyperplasia (BPH) is a common disorder that will affect nearly
all men at some point in their life. BPH normally occurs in two distinct phases 120.
During the first phase of disease progression, there is microscopic evidence that the
glandular cells of the prostate increase in size. The second phase of BPH progression
results in dysuria caused by macroscopic growth of the prostate gland resulting in partial
obstruction of the prostatic urethra. It is generally thought that the presence of BPH does
not increase a patient’s risk of developing CaP. The level of miR-125b decreases in BPH
cells when compared to normal benign epithelium (Figure 3-13). However, there is a
great range of miR-125b levels in BPH cells as evident by the large standard deviation. It
would be interesting to determine if BPH glands located closer to tumor cells display an
altered miRNA expression portrait.
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Figure 3-13: Evaluation of miR-125b expression in various epithelial subtypes
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Figure 3-13: Evaluation of miR-125b expression in various epithelial subtypes
A single FFPE prostate sample mounted in 10μm slices onto 20 slides was dissected with
LCM into various epithelial subtypes and stroma. Using the PicoPure RNA extraction kit,
total RNA was obtained and quantity estimated using an Agilent Bioanalyzer 2100 with
the RNA Pico chip. RNA (20 ng) was converted into cDNA using the TaqMan®
microRNA Reverse Transcription Kit (Life Technologies, Grand Island, NY). Q-PCR
was performed with specific primers against miR-125b using the TaqMan® Universal
Master Mix II with no Amp unerase (Life Technologies, Grand Island, NY). CT values
were normalized using levels of the endogenous control (RNU48) and reported as fold
differences using the ddCT method of Livak et al 74.
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Prostatic intraepithelial neoplasia (PIN) is considered to be a pre-cursor for the
development of prostate carcinoma 121. PIN is characterized by increased proliferation of
basal cells in the prostate gland without invasion into the underlying stroma. Many of the
genetic changes that drive prostate cancer occur early in pathogenesis and are evident in
PIN cells. Expression of the EGFR members ERBB2/ ERBB3 increase as the cells
transition from a benign phenotype to PIN cells 122. As ERBB2/ ERBB3 are targeted by
miR-125b, it is reasonable to suspect that miR-125b decreases as the cells transition. Our
analysis confirms this hypothesis. miR-125b decreases 3- 4-fold when compared to the
benign epithelium (Figure 3-13). This finding indicates the miR-125b may be useful to
identify early pre-cancerous lesions and subsequent decreases in the level of miR-125b
may help identify progressive tumor growth.
In order for a tumor cell to set up a distant metastatic lesion, it must detach from
its neighbors and invade the surrounding basement membrane. Numerous proteins have
been implicated in the ability of a cell to acquire metastatic potential 123. Two proteins
that affect the PI3K/ AKT pathway have been shown to impact the metastatic potential of
a cell. Over-expression of ERBB2/ ERBB3 has been shown to increase a cell’s ability to
become motile and invasive. Loss or reduction of PTEN has a similar phenotypic effect.
Due to the combinatorial analysis implicating ERBB2/ ERBB3 as potential
drivers of tumorigenesis negatively regulated by miR-125b whose level is reduced as
tumorigenicity increases, it is reasonable to suspect that restoration of miR-125b would
inhibit tumorigenic potential. Many studies have used miRNA overexpression as a means
to identify function of the miRNA 124. Literature shows that the enforced expression of
miR-125b impacts a cells ability to invade and migrate through the stroma of the prostate
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tissue 125. Proof of this concept also exists in breast cancer where it was shown that
increased expression of miR-125b in SKBR3 cells inhibits the ability of cells to migrate
and invade through the down regulation of ERBB2/ERBB3 106. Down-regulation of miR125b is found in many solid tumors and promotes anchorage independent proliferation,
cell migration and invasion. Loss of miR-125b seems to be an important step in the
attainment of an oncogenic state.

In Vitro metastasis assays
Stable transformation of M12 cells with a pSIREN vector expressing the pre-mir125b sequence negatively affected the ability of M12 cells to migrate (Figure 3-14). After
transfection and selection, restoration of expression was confirmed by qRT- PCR and the
level of miR-125b was found to be 3-fold higher than the original M12 cells (Figure 315). It is important to note that this fold of expression change is physiologically relevant.
Most human tumors profiled in this study had a 3 - 5-fold drop in the level of miR-125b.
Enforced overexpression of a miRNA past physiological levels may not reveal accurate
results.
Previous studies have demonstrated that restoration of a tumor suppressing
miRNA (hsa-miR-17-3p) limits the ability of M12 cells to migrate in a Transwell assay 90.
It is known that miR-17-3p downregulates the intermediate filament protein, vimentin,
which is known to increase in highly tumorigenic, metastatic cells. M12 cells stably
expressing mature miR-17-3p were used as a positive control to compare our miR-125b
expressing cells. Like miR-17-3p, restoration of miR-125b expression inhibited cellular
migration approximately 3- 4-fold.
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Figure 3-14: Migration assay
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Figure 3-14: Migration assay
Cells (50,000) were plated in serum free media in the top chamber of a ThinCert™ tissue
culture insert. Bottom chamber contained 500 μl of RPMI 1640, 5% FBS, supplemented
with 10 ng/ml of EGF as a chemotractant agent. Cells were incubated for 20 hours and
fixed with 0.025% glutaraldehyde for at least 20 minutes. Cells visualized by staining
with 0.1% crystal violet in PBS for 30 minutes and the membrane was mounted on a
glass slide. Cells were plated in triplicate across three wells and counted in 10 random
fields. Total number of migratory cells was estimated by summing up each of the
individual fields. The mean sum of the well is presented, along with the standard error.
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Figure 3-15: Restoration of miR-125b in M12 cells
3.5

Fold change relative to P69

3
2.5
2
Fold
1.5
1
0.5
0
M12

M12+125b
Cell Line

Figure 3-15: Restoration of miR-125b in M12 cells
M12 cells (500,000) were stably transformed with the human miR-125b sequence. Cells
were transformed with purified plasmid (2.0 μg) using TransIT-LT1 (4.0 μl) transfection
reagent (Mirus BioCorp, Madison, WI). Resistant cells were selected with 400 ng/ml
Puramycin. Increased expression of miR-125b was verified by TaqMan™ qRT-PCR
analysis.
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Secondary tumor sites are a culmination of a metastatic cascade of events in
which the tumor cell becomes motile and invades the basement membrane 126.
Restoration of miR-125b reduces the motility of cancer cells as evidenced by the
Transwell assay shown in Figure 3-14. Invasion of a cell through the basement membrane
is critical to the ability of a tumor to disseminate to other organs. The invasive potential
of M12 cells with restored miR-125b was assessed using Transwell chambers coated with
reduced growth factor basement membrane. Untreated M12 cells were highly invasive.
M12 cells with restored miR-125b had a 75% lower invasive ability than M12 cells
(Figure 3-16). Again the results are quite similar to M12 cells with restored expression of
miR-17-3p.
Together these assays suggest that restoration of miR-125b negatively impacts a
tumor cell’s ability to metastasize. As most patients that die from prostate cancer, die
from metastatic lesions, inhibition of metastasis may prolong the lives of patients
suffering from prostate cancer. Targeted delivery of miR-125b to prostate cancer cells
may offer a unique therapeutic alternative to limit morbidity and mortality associated
with the disease. These analyses demonstrate that progressive loss of miR-125b increases
the metastatic potential of tumor cells.
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Figure 3-16: Invasion assay
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Figure 3-16: Invasion assay
Cells (50,000) were plated in serum free media in the top chamber of a ThinCert™ tissue
culture insert. Bottom chamber contained 500μl of RPMI 1640, 5% FBS, supplemented
with 10ng/ml of EGF as a chemotractant agent. Membrane was coated with Culturex®
growth factor reduced basement membrane (60μl). Cells were incubated for 20 hours and
fixed with 0.025% glutaraldehyde for at least 20 minutes. Cells visualized by staining
with 0.1% crystal violet in PBS for 30 minutes and the membrane was mounted on a
glass slide. Cells were plated in triplicate across three wells and counted in 10 random
fields. Total number of migratory cells was estimated by summing up each of the
individual fields. The mean sum of the well is presented, along with the standard error.
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Chapter 4
Reverse phase microArray identifies key proteins regulating cell growth
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Reason for proteomics
Proteins have long been considered the workhorse of biological molecules. They
are involved in nearly every cellular process from regulation of cell growth to initiation
of apoptosis. Aberrant protein signaling pathways influence many processes that aid in
tumorigenesis 37. Traditionally, gene array profiling has been used to distinguish genes
that are dysregulated during the development of disease. It was traditionally thought that
mRNA expression reflected actual protein levels. Knowledge of post-transcriptional
control affecting mRNA translation challenges this traditional theory. It is now known
that most genes are influenced by at least one miRNA. Thus, mRNA expression
correlates poorly with protein levels.
A more useful comparison would be miRNAs to protein levels, since protein
synthesis is the direct target for miRNA regulation. It is true that some miRNA targeting
results in mRNA degradation, but the more common outcome is a halt of translation.
Although both methods of attack results in decreased protein levels, differences in
mRNA expression correlate poorly with protein levels. Actually, few mRNAs have been
shown to be degraded by miRNA binding. Obviously, direct measurement of protein
content via a proteomic approach would be a better indicator of overall miRNA
regulation than gene arrays. Unfortunately, gene arrays have been inappropriately used
for this purpose, as they are freely available, relatively inexpensive and easily applied
even by a novice. Proteomic arrays, on the other hand, require considerable expertise, a
bevy of well characterized optimized antibodies and are not easily duplicated by the
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novice. However, in order to identify proteins contributing to the development of CaP,
one must utilize a high throughput proteomic method
Identifying key proteins that are dysregulated during tumorigenesis may reveal
common pathways that are altered during cancer progression. Cellular fate is determined
by minute fluctuations in the proteome of the cell 37. The reverse phase protein
microarray (RPMA) immobilizes hundreds of cellular lysates onto a nitrocellulose glass
slide in a miniature dilution curve 112. The slide is probed with an antibody to the protein
of interest and the level of the protein is accurately determined. This method requires one
slide for each antibody of interest. In this capacity, we have been assisted by Drs. Lance
Liottta and Emmanuel Petricoin III from George Mason University, leaders of this
technology. Ultimately, the method is high throughput allowing a researcher to quantify
hundreds of proteins across hundreds of samples.

Materials and Methods
Cell culture
Cells are cultured at 37° C in RPMI1640 with L-glutamine obtained from Gibco
supplemented with 5% fetal bovine serum, 5 μg/ml insulin, 5 μg/ml transferrin, and 5
μg/ml of selenium (ITS from Collaborative Research Bedford, MA). Inhibition of
bacterial contamination was accomplished with the addition of Gentamycin (0.05 mg/ml).
M12 cells stably transformed with the p-SIREN (M12+miR-17-3p and M12+miR-125b)
vector were maintained with Puromycin (100 ng/ml). F6 cells were maintained with
Geneticin (200 μg/ml) 24. All tissue culture cells were grown in T75 flasks and split when
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confluent. Cells were pelleted after trypsin (0.25% in EDTA) digestion by centrifugation
at 5000 RPM for five minutes. After washing, cell pellets were flash frozen in liquid
nitrogen after washing and stored for at least 24 hours. Three representative cell pellets
were harvested during three serial passages for a total of 9 samples analyzed for each
sample type was sent to the George Mason University Center for Applied Proteomics and
Molecular Medicine. Overall, a total of 12 cell types were sent for RPMA analysis. All
cell types were variants of the progression model described and many were designed to
overexpress miRNAs of interest.

Reverse phase microarray
RPMA experiments were conducted at the George Mason University Center for
Applied Proteomics and Molecular Medicine under the supervision of Dr Emmanuel
Petricoin III. It is important to note that the cell pellets used for RNA extraction for
miRNA profiling were also used for proteomics analysis. This approach minimizes
variation from culture to culture. Briefly, cell pellets were lysed in a tissue extraction
buffer and spotted on the nitrocellulose coated glass slide. Each lysate was spotted in a
miniature dilution curve (1:1, 1:2, 1:4, 1:8, and 1:16) to ensure accurate quantification of
each protein measured. Overall, the cellular lysate was spotted onto 111 slides and each
incubated with a unique antibody. Data were returned to our group on a Microsoft Excel
spreadsheet containing each cell type analyzed with each antibody of interest.
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Statistical analysis
Using Microsoft Excel, a two sample equal variance T-test was used to test for
significant differences among the P69 cells and M12 cells. The significance value was set
at α = 0.05.

Results
Significantly different proteins
Although there were a total of 12 cell types sent for RPMA evaluation, this study
focuses on the P69 and M12 variants. It was found that there were 17 significantly
dysregulated proteins between P69 and M12 cells (Table 4-1). Comparing the set of
dysregulated proteins to our subset of miRNAs dyesregulated during tumorigenesis
revealed several proteins regulated in part by miR-125b. Due to our proven interest in
miR125b, we have concentrated on these targeted proteins first. Loss of miR-125b
causes an increase during the transformation to a more tumorigenic phenotype of ErbB2
(2-fold) / ErbB3 (2.1-fold) and PI3K (1.5-fold) (Figure 4-1). As mentioned previously,
activation of the PI3K/ AKT pathway increases cellular proliferation, invasion and
metastasis. Activation of the PI3K/ AKT pathway plays a central role in the development
of an oncogenic phenotype 127. AKT activation is an essential survival mechanism in
many cell types and is found in numerous forms of cancer including CaP.
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Table 4-1: Statistically significant proteomics changes determined using RPMA

Protein

Fold change

Receptor Tyrosine Kinase
ErbB2

1.8

ErbB3

2

p-ErbB3

1.3

p-PI3K

1.4

p-BAD

1.7

p c-KIT

700

Cell Cycle
p27

0.7

Cyclin B1

0.6

Apoptosis
p-BCL2

1.2

Cytochrome C

0.4

Caspase 7

1.5

Others
Androgen Receptor

1.7

p-c-KIT

700

CD44

0.2

p-GSK3A/B

1.2
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Figure 4-1: Model of AKT activation in prostate cancer
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Figure 4-1: Model of AKT activation in prostate cancer
Combinatorial analysis of miRNA expression profiling and reverse phase proteomics
reveals activation of the PI3K/ AKT pathway. Inhibition of miR-125b leads to increased
expression of ERBB2/ ERBB3, thereby accelerating proliferation and inhibiting
apoptosis. Nodes in red have been shown to be lost during prostate cancer development.
Nodes in green increases as the tumor became more oncogenic. Nodes in yellow were not
either not statistically significant or were not able to be assessed in the current study as
antibodies were not included.
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Literature shows that dysregulated PI3K activity is a major contributor to
oncogenic transformation 128. Increased activity of PI3K increases phosphorylation of
AKT and affects a number of downstream targets that impart oncogenic potential.
Proteomics analysis shows that increased expression of both ErbB2 and ErbB3 lead to a
statistically significant increase in the phosphorylation of PI3K (p-value = 0.002) (Figure
4-2). AKT is activated by phosphorylation of two potential residues, serine-473 and
threonine-308. Although not statistically significant, our results show a trend toward
increased phosphorylation of serine-473. It is possible that with an increased sample
number, we may be able to further resolve differences between samples and statistically
show an increase in AKT activation.
AKT activation causes phosphorylation of BAD, a BCL-2 family member that
induces apoptosis. Apoptosis results from the interaction of BAD and the BCL-Xl protein.
In absence of phosphorylation, BAD induces cell death by phosphorylation of either
serine-112 or serine-136 129. Phospho-BAD binds to 14-3-3 protein which sequesters
BAD and inhibits apoptosis. Our analysis shows an increase in the phosphorylation of
BAD, but not an increase in the basal expression of BAD. Taken together this data
demonstrates that ErbB2/ ErbB3 accumulation activates the PI3K/ AKT pathway and
inhibits apoptosis through phosphorylation of BAD.
RAS protein is a membrane bound protein that exists in 2 states of activation 130.
When a GDP molecule is bound to the cytoplasmic side of the protein, RAS is inactive.
GTP binding activates the RAS molecule and initiates a

- 118 -

Figure 4-2: Pathways increased during prostate tumorigenesis
Analysis of RPMA data revealed that common members of the PI3K/ AKT pathway are
activated during conversion of P69 cells to the more tumorigenic M12 variant.
Overexpression of ErBB2/ ErbB3 and p-MET can also lead to activation of the RAS
oncogenic pathway. Protein nodes in green were shown to be significantly upregulated
during tumorigenesis (p-value <0.05). Proteins in yellow were not statistically significant.
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Figure 4-2: Pathways increased during prostate tumorigenesis
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series of events inside of the cell that ultimately results in cell proliferation, cellular
differentiation, cell survival, and an increase in cell motility.
ErbB2/ ErbB3 phosphorylation recruits the growth-factor-receptor-bound-protein
2 (GRB2) bound to SOS to the plasma membrane 130. SOS recruitment to the membrane
brings it in close proximity to the RAS molecule. Due to their proximity, a nucleotide
exchange occurs between the two proteins activating RAS. RAS activation sets off a
cascade of events, ultimately ending in phosphorylation of ERK. The phosphorylation of
MEK1 is an intermediate step in the activation of ERK. ERK can affect numerous targets
in the nucleus. Transcription factors regulated by p-ERK affect proliferation,
differentiation, cell survival and motility.
Our data show that downstream targets of RAS such as p-MEK and p-ERK are
more active in the highly tumorigenic, metastatic M12 variant. There is approximately 5fold more p-ERK present in the M12 variant than there is in the P69 parental cell (pvalue=0.03). Over expression and activation of the EGFR receptors (ErbB2/ErbB3)
activate two downstream pathways that independently affect proliferation, apoptosis, and
mobility. Targeted therapies against only one pathway are likely to be ineffective.
However, re-expression of miR-125b may be a viable alternative that can inhibit both the
PI3K/AKT and the MAPK/ ERK pathways through repression of ErbB2 and ErbB3.
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Chapter 5
Summary and discussion
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Prostate cancer is a leading cause of death of men in the United States; it is
estimated that 1 in 6 men will be affected by prostate carcinoma at some point in their life.
Cancer development is a multifactorial process influenced by age, ethnicity, and sexual
factors. These factors influence a person’s risk of developing prostate cancer.
Traditionally, CaP was diagnosed with a digital rectal exam followed by transrectal
biopsy of the gland. The advent of the PSA biomarker increased the likelihood of a man’s
compliance with active screening methods. However, as it has become clear that the PSA
test is not a reliable indicator of prostate cancer formation, there has become a need to
develop more accurate biomarkers. Diagnostic rates have declined in the last few years,
particularly in the African-American population and in persons without a college
education. It is known that African-Americans have a much higher death rate from
prostate cancer than their Caucasian counterparts. Biomarkers that are non-invasive and
can indicate early tumor formation are critically needed to minimize death and suffering
from this disease.
In recent years, miRNAs have gained attention as important mediators of
numerous cellular processes. Differential regulation has been observed in the
development of numerous pathologies including cancer. This study has shown that
miRNAs tend to regulate highly connected proteins and transcription factors affecting
numerous downstream cellular pathways when dysregulated. Additionally, we have
demonstrated that highly connected proteins are more likely to be regulated by more than
one miRNA. Thus, dysregulation of even a single miRNA may impact intracellular
stability and induce oncogenic transformation.
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MiRNA dysregulation is a wide spread problem occurring during the
development of prostate cancer. Using a unique genetically related prostate cancer cell
progression model, we identified approximately 200 miRNAs that potentially influence
cancer initiation, progression and metastasis. Initial profiling was accomplished with the
Exiqon miRCURY LNA™ based array platform. As miRNAs influence posttranscriptional regulation of proteins, we identified key highly connected proteins using
an innovative networks approach. Dysregulated miRNAs were ranked according to the
sum connectivity of their proven targets. A subset of miRNAs was chosen for evaluation
across all variants of the cancer progression model (5 oncomiRs, 3 tumor suppressors).
Although all were identified to be dysregulated using the miRCURY array, several did
not agree in estimated fold changes to single miRNA analyses. We conclude that array
based platforms are ideal to determine gross regulation differences but true fold changes
are only detectable with a single assay format.
miRNA changes were assessed using pure cell populations obtained after
microdissection of human prostate tumor samples. Interestingly, only the identified tumor
suppressors were universally confirmed in all of the human samples included in the study.
One patient sample showed that many of the proposed oncomiRs increased during
tumorigenesis but not all. This finding suggests that increased expression of oncomiRs
may be tumor type dependent but loss of tumor suppressors is more universal. There are
many mechanisms in which a tumor suppressor may be lost including epigenetic
modification.
Our unique combinatorial approach integrated a bioinformatically driven
networks method with high throughput miRNA screening and reverse phase proteomics
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to identify key miRNAs and pathways associated with prostate cancer progression. This
approach indicated that miR-125b may be an essential miRNA that drives prostate cancer
progression as it is lost during the conversion of benign cells toward a more oncogenic
state. At this point, our analysis focused in on miR-125b because of its regulation of the
PI3K/ AKT pathway and its known involvement in cancer progression and initiation of
metastasis. However, much of the knowledge regarding miR-125b dysregulation was
discovered in breast cancer. Previous researchers have demonstrated that miR125b
inhibits translation of the ERBB2/ ERBB3 members of the epidermal growth factor
receptor family 106. Analysis of miR-125b expression across epithelial subtypes showed
that its level began decreasing in early pre-cancerous lesions (PIN) and the level
continued to decline as the cancer progressed. .
Support of a potential role of miR-125b affecting the PI3K/ AKT pathway was
found using a reverse phase proteomics array in which we observed an increase in
ERBB2/ ERBB3 and PI3K. The loss of miR-125b results in an increase in the level of
ERBB2/ERBB3 and increased activation of PI3K. Stable restoration of miR-125b in M12
cells decreased metastatic capability as evidenced by decreased cell migration and
invasion through a basement membrane.
Various human tumors demonstrate progressive loss of miR-125b, suggesting that
miR-125b may be a common tumor suppressor in numerous types of cancers 131.
However, there have been conflicting findings with some studies showing an increase in
the level of miR-125b, while others have shown that miR-125b decreases in prostate
cancer development. As discussed previously, miR-125b is dependent upon androgen
sensitivity during the development of CaP.
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There has been a large amount of effort in determining the role of miR-125b and
ErbB2/ ErbB3 in breast cancer. Numerous reports have shown that loss of miR-125b in
breast cancer decreases chances of survival and increases the likelihood of metastasis 131.
Two potential CpG rich islands were located within 2000 bp upstream of miR-125b. One
of the potential CpG islands was shown to be heavily methylated in highly tumorigenic
cell lines and invasive breast cancer tissue. Treatment with 5-AZA-Cr restored expression
of miR-125b. Taken together these data demonstrate that hypermethylation of the
promoter of miR-125b decreases its expression in breast cancer.
Although there is ample evidence that loss of miR-125b occurs frequently in the
development of breast cancer and its loss directly affects the levels of ErbB2/ErbB3.
There is little evidence in prostate cancer for a role of miR-125b. Our study clearly
demonstrates that in androgen independent sublines, miR-125b functions as a tumor
suppressor. Similar to the study conducted by Ozen et al, our study found that miR-125b
decreased in all prostate cancer tumors analyzed 115. Findings of this study confirm that
miR-125b functions as a suppressor of tumor formation in the prostate gland and
increases coordinately the levels of ErbB2/ErbB3 activating the PI3K/AKT and RAS
oncogenes pathways. Taken together, these data suggest that loss of miR-125b may be an
ideal biomarker for the identification of prostate cancer and potentially be used as a
therapy to inhibit metastatic potential.
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